The Dietary Isoprenoid Perillyl Alcohol Inhibits Telomerase Activity in Prostate Cancer Cells by Sundin, Tabetha
Old Dominion University 
ODU Digital Commons 
Theses and Dissertations in Biomedical 
Sciences College of Sciences 
Spring 2012 
The Dietary Isoprenoid Perillyl Alcohol Inhibits Telomerase 
Activity in Prostate Cancer Cells 
Tabetha Sundin 
Old Dominion University 
Follow this and additional works at: https://digitalcommons.odu.edu/biomedicalsciences_etds 
 Part of the Cell Biology Commons, Genetics Commons, and the Molecular Biology Commons 
Recommended Citation 
Sundin, Tabetha. "The Dietary Isoprenoid Perillyl Alcohol Inhibits Telomerase Activity in Prostate Cancer 
Cells" (2012). Doctor of Philosophy (PhD), Dissertation, , Old Dominion University, DOI: 10.25777/
nnr5-bx62 
https://digitalcommons.odu.edu/biomedicalsciences_etds/80 
This Dissertation is brought to you for free and open access by the College of Sciences at ODU Digital Commons. It 
has been accepted for inclusion in Theses and Dissertations in Biomedical Sciences by an authorized administrator 
of ODU Digital Commons. For more information, please contact digitalcommons@odu.edu. 
THE DIETARY ISOPRENOID PERILLYL ALCOHOL INHIBITS TELOMERASE 
ACTIVITY IN PROSTATE CANCER CELLS 
B.S. May 2005, Old Dominion University 
A Thesis Submitted to the Faculty of 
Old Dominion University in Partial Fulfillment of the 
Requirements for the Degree of 
DOCTOR OF PHILOSOPHY 
BIOMEDICAL SCIENCES 




Approved by : 
PatriGia Hento^MCo-Advisor) 
ABSTRACT 
THE DIETARY ISOPRENOID PERILLYL ALCOHOL INHIBITS TELOMERASE 
ACTIVITY IN PROSTATE CANCER CELLS 
Tabetha Sundin 
Old Dominion University, 2012 
Co-Advisors: Dr. Patricia Hentosh 
Dr. David Gauthier 
This is the first evidence that a plant-derived compound-perillyl alcohol -
regulates telomerase activity via the mammalian target of rapamycin (mTOR) 
pathway in prostate cancer cells. Telomerase-the enzyme responsible for 
immortalizing cells through telomeric repeats addition-is de-repressed early in 
an aspiring cancer cell. We hypothesized that perillyl alcohol regulates hTERT 
(human telomerase reverse transcriptase) at the translational and post-
translational levels via its effects on the mTOR pathway. A rapid suppression 
of telomerase activity was detected in prostate cancer cell lines (PC-3 and 
DU145) in response to biologically-relevant concentrations and short 
incubations of perillyl alcohol or the mTOR inhibitor-rapamycin. 
Western blot analysis revealed a decrease in hTERT protein levels in 
response to either agent that did not coincide wholly, with loss of telomerase 
activity suggesting a further level of regulation. Using immunoprecipitation we 
established the presence of a hTERT-mTOR-S6K (p70 S6 kinase)-Hsp90 (Heat 
shock protein 90)-Akt complex previously detected in activated NK cells in 
DU145 prostate cancer cells. Further, western blot analysis demonstrated that 
perillyl alcohol or rapamycin disrupted the binding interactions between 
RAPTOR and hTERT, mTOR, S6K, and Hsp90, establishing an additional 
mechanism by which these agents decrease telomerase activity. 
Prostate cancer cells overexpress elF4E (eukaryotic initiation factor 4E) 
the rate-limiting protein that mediates cap-dependent translation by way of 
mTOR signaling. Immortalized Chinese hamster ovary (CHO) control cells 
(pMV7) and CHO cells with forced elF4E-overexpression (rb4E) were used to 
elucidate the role of elF4E in telomerase regulation by perillyl alcohol and 
rapamycin. Telomerase activity and TERT protein levels were dramatically 
attenuated in rb4E cells by perillyl alcohol or rapamycin, but the pMV7 cells 
were unresponsive to either agent. Through western blot analysis we 
determined elF4E-overexpression activates Akt-an upstream regulator of 
mTOR-through a positive-feedback loop thereby increasing the 
phosphorylation of downstream targets of Akt. These findings demonstrate that 
elF4E-overexpression in CHO cells alters protein synthetic processes and gene 
regulation, thus enabling the inhibitory effects of perillyl alcohol and rapamycin 
on telomerase activity and TERT protein levels. This study provides evidence 
for a unique link between perillyl alcohol- and rapamycin-mediated regulation of 
mTOR and hTERT. 
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CHAPTER I 
INTRODUCTION, SPECIFIC AIMS AND SIGNIFICANCE 
INTRODUCTION 
Telomeres 
Human telomeres, specialized nucleoprotein structures found at the ends 
of chromosomes, consist of a repeated series of the hexameric DNA sequence 
(TTAGGG)n, along with a 6-protein complex called shelterin (Fig. 1) [1-3]. 
Telomeres function to prevent chromosomal degradation and genomic instability 
and therefore the loss of genetic information. Although human telomeres are of 
heterogeneous lengths, human cells begin with approximately 12 kilobases (kb) 
of telomeric DNA; by the time adulthood is reach this number has been reduced 
to around 8 kb of telomeric DNA [4], Therefore, telomeres function as molecular 
clocks that ultimately link cellular aging to cell division [5]. DNA polymerases 
require a double-strand/single strand interface in order to bind DNA and therefore 
replicate the strands. The interface is provided by an RNA primer laid down by 
an RNA primase. Although only used once at the beginning of replication for the 
leading strand, this RNA primer is used repeatedly for the lagging strand. After 
DNA polymerase a uses the primer to initiate replication, RNA sequences are 
removed, degraded and replaced by DNA. Space becomes limiting at the 3'-end 
of the lagging strand, and the RNA primase may no longer bind the strand to 
provide an interface. Therefore, DNA polymerase cannot fully replicate the 
lagging strand resulting in a single-stranded 3' overhang that will eventually be 
cleaved off leading to DNA loss. 
The journal format for this dissertation is modeled after Archives of Biochemistry 
and Biophysics 
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Fig. 1. The shelterin complex, (a) The six protein complex that constitutes 
shelterin. (b) Schematic of shelterin complex bound to a telomere. TRF1 and 
TRF2 bind both double-stranded TTAGGG repeats and TIN2. TIN2 also binds 
TPP1, which binds POT1. POT1 binds the single-stranded portion of the 
telomere end, creating the D-loop. Reprinted from DNA Repair, 8, Give me a 
break: How telomeres suppress the DNA damage response, page 1119, © 2009 
Elsevier B.V., with permission from Elsevier. [1]. 
The inability of DNA polymerase to replicate DNA to the end of the chromosome 
is referred to as the 'end replication problem' [6, 7]. The telomeric repeat 
(TTAGGG) is non-coding, serving only as a substitute for the loss of 
chromosomal DNA that may otherwise occur during replication. 
In humans, the protein complex shelterin protects the single-stranded 3'-
end of the telomere by inducing secondary structure formation. The 3' single-
stranded overhang is tucked back into the double-stranded telomeric DNA 
creating a t-loop and a D-loop (Fig. 1 (b)) [1, 8]. This secondary structure acts to 
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sequester the 3' single-stranded overhang from cellular repair proteins so that it 
will not be recognized as a single-stranded break [9], Shelterin is composed of: 
telomeric repeat binding factors 1 and 2 (TRF1/2), TRF2- and TRF1-Interacting 
nuclear protein 2 (TIN2), protector of the telomere (POT1), the human ortholog of 
the yeast repressor/activator protein 1 (RAP)1, and the protein formerly known as 
TINT1, PTOP, or PIP1 (TPP1) (Fig. 1 (a)) [10]. Despite the efforts of shelterin, 
50-200 bp of telomeric DNA are lost with each round of replication [11], When 
telomeres reach a pre-determined critically short length (< 200 bp), the 
secondary structure provided by shelterin is disrupted [12]. Through a complex 
signaling cascade, the loss of secondary structure provided by shelterin signals 
the cells to go into an irreversible state termed senescence [12]. Although the 
cell is viable during senescence, it is unable to proliferate. Without further 
damage the cell can remain in the senescent state for long periods of time. 
Chromosomes that lack sufficient telomeric repeats are prone to chromosomal 
degradation, recombination and fusion events. In this manner, telomeres act as 
the protective cap at the end of the chromosome and have been likened to the 
plastic tips at the end of a shoelace [13]. 
Telomerase 
The hexameric repeats (TTAGGG)n at the ends of telomeres are 
synthesized and maintained by an enzyme called telomerase [14]. Telomerase 
is a ribonucleoprotein, consisting of three major components: human telomerase 
reverse transcriptase (hTERT), human telomerase RNA component (hTERC), 
and the protein dyskerin, all of which are necessary to counteract telomeric 
shortening during replication [15-18]. Human TERT is a DNA polymerase that is 
also classified as a reverse transcriptase (RT) due to its ability to copy an RNA 
template into DNA [15]. Blackburn, Greider and Szostak shared the Nobel Prize 
in 2009 for their work with telomeres and their discovery of telomerase. Although 
both hTERT and hTERC are necessary for telomerase activation, hTERT is the 
catalytic portion of the enzyme and is considered the rate-limiting component [19, 
20]. In fact, when the TERT gene is transfected into human cell lines under the 
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control of a constitutive promoter, the cells bypass senescence and become 
immortal [21]. Three structural components comprise hTERT: a long N-terminus 
with DNA and RNA-binding domains, a catalytic reverse-transcriptase domain, 
and a short C-terminus extension [22], Similar to most other polymerases, there 
are notable fingers, palm and thumb DNA polymerase motifs found in the TERT 
protein [23, 24]. 
The hTERC portion of telomerase enzyme consists of an 11-nucleotide 
template core region that provides the RNA template for the enzyme to generate 
telomeric repeats [25], In addition to a template region, hTERC has a conserved 
region 4 and 5 (CR4/CR5), a pseudoknot motif and the box H and ACA elements 
(H/ACA domain) that provide enzyme fidelity, processivity, and are responsible 
for the interaction between hTERT and hTERC [26]. Dyskerin, the protein 
portion of the telomerase holoenzyme, is necessary for enzymatic regulation. 
Current research favors the model of dyskerin along with two ATPases, pontin 
and reptin, serving to stabilize hTERC, while hTERC and hTERT assemble. 
Although pontin and reptin dissociate, dyskerin remains a part of the active 
enzyme [27]. Once all components are together in the complex, telomerase 
becomes active and synthesizes telomeric repeats. 
Telomerase extends telomeres through a reaction involving cycles of 
primer recognition and binding, synthesis and translocation. Through this 
reaction, telomerase adds hundreds of nucleotides to the DNA strand. The first 
part of the reaction, primer recognition and binding, is carried out once 
telomerase recognizes the 3' single-stranded overhang of the telomere that 
serves as the DNA primer for this polymerase [24], Telomerase recognizes the 
guanine-rich strand of the telomere as a primer in vivo; it also appears that any 
guanine-rich template can serve as a primer for telomerase in vitro [28], During 
the synthetic portion of the cell cycle, telomerase processively adds 
deoxynucleoside triphosphates (dNTPs) to the end of the telomere, known as 
repeat addition processivity. During synthesis, the RNA-DNA hybrid is kept at a 
constant length of seven to eight base pairs, due to 5'-bonds melting and 3'-
bonds being created at the same rate [29]. When the telomerase enzyme 
5 
reaches the 5'-end of the template, it translocates to reposition the DNA at the 3'-
end of the template to repeat the cycle. The ability of telomerase to add repeats 
processively is unique. Most reverse transcriptases are only able to copy an 
RNA genome into a single DNA molecule. Telomerase is capable of repeat 
addition processivity due to DNA-binding 'anchor sites' that are present in hTERT 
[30]. In addition to anchor sites, it has also been shown (in vitro) that the 
telomere-binding protein heterodimer TPP1-POT1 stimulates telomerase activity 
and processivity, although the mechanism by which this occurs has not been 
elucidated [31]. 
Telomerase and Cancer 
Generally, somatic cells and normal cells in culture lack hTERT 
expression, so their telomere length continues to shorten with each cell 
replication. Consequently, these telomerase-deficient cells have a limited 
number of cell divisions prior to senescence, or a non-replicative state [9], Some 
sub-populations of normal human cells do express low levels of telomerase that 
are insufficient to achieve immortality. These include mainly stem cells in 
proliferating tissues, germ cells, and activated lymphocytes [32-34], Telomerase 
activation or derepression is a critical event in a cell that is progressing towards a 
cancerous state [35], Activating/de-repressing telomerase immortalizes ~90% of 
cancer cells [36]. The other ~10% of cancer cells activate a mechanism known 
as alternative lengthening of telomeres (ALT), in which recombination events 
lead to the extension of the telomere [37], Telomerase expression does not 
make a cell cancerous, but allows a cell to live long enough to acquire mutations 
that increase its likelihood of becoming cancerous. Mouse models have shown 
that overexpression of TERT leads to increased tumor formation [38, 39]. This 
low level of telomerase is not sufficient to prevent the telomere from shortening, 
but it does slow the rate at which the process occurs [40]. Cancer cells have 
shorter telomeres than normal cells, sensitizing them to telomerase inhibition 
[41]. Therefore telomerase inhibition is an attractive target for cancer therapy. 
Telomerase inhibition in cancer cells has been shown to decrease telomere 
length and cause cellular senescence or apoptosis, while having little effect on 
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normal cells [41]. Telomerase inhibitors thus have a promising role as adjuvant 
therapeutics or as chemopreventives [42]. Telomerase inhibition is a key target 
for anticancer studies due to the specificity of telomerase expression and the 
correlation between telomerase presence and cell immortality. 
Telomerase Regulation 
The rate-limiting component of the telomerase holoenzyme, hTERT, is 
regulated at both the transcriptional and post-transcriptional level. hTERT mRNA 
levels are controlled through a series of transcriptional factor interactions with 
promoter regions. Posttranscriptional control mechanisms such as structural 
changes of the holoenzyme, localization of hTERT, hTERT phosphorylation, 
protein degradation and alternative splicing account for a significant degree of 
regulation [43], A critical level of regulation is governed by transcriptional 
processes [44], Somatic cells and normal cells in culture do not have detectable 
levels of hTERT mRNA, although the RNA component-hTERC-is transcribed and 
present at finely regulated levels [19, 45], Eventually normal cultured cells with a 
finite number of growth divisions will enter into a stage of growth arrest, termed 
senescence. In time the telomeres of these cells will become so short that the 
ends of the chromosomes began to fuse and break. This cellular stage is termed 
crisis; all but a few of these cells will succumb to apoptotic death [46], The 
limited number of cells that survive crisis become immortalized, a process 
characterized by a surge in hTERT mRNA levels [45]. Comparable 
transcriptional derepression of hTERT is observed in tumor cells relative to 
adjacent normal tissues [45]. The promoter region of the hTERT gene has 
multiple binding sites for a vast array of transcription factors (both activators and 
repressors), providing clues to the extent of regulatory complexity [47]. 
Specifically, two Myc/Max binding sites (E-boxes) have been identified in the 
hTERT promoter, and c-myc directly activates hTERT transcription [48-50]. 
Alternatively, Mad-1 can displace Myc and form a heterodimer with Max, thereby 
repressing transcription by blocking the E-box found in the hTERT promoter [51]. 
The human papillomavirus type 16 E6 oncoprotein (E6) also binds the E-box, 
thereby activating hTERT [52]. Myc is not the only transcription factor that can 
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alter hTERT expression. Estrogen has been shown to activate telomerase via 
effects on the hTERT promoter [53]. 
Adding to the complexity of hTERT transcriptional regulation, signal 
transducer and activator of transcription (STAT)3 and STAT5 bind the promoter 
of hTERT [54], Telomerase is also upregulated by hypoxia-inducible factor-1 
(HIF-1) and via portions of the Ras (rat sarcoma) pathway [55, 56]. Additionally, 
leptin, an adipose-secreted hormone, increases the expression of hTERT mRNA 
and protein, providing a mechanism of action to explain the increased cancer 
incidence in obese patients [57], Telomerase expression is inhibited 
transcriptionally by the p53-mediated binding of the transcription factor, Sp1 [58]. 
Almost all cancer cells have aberrant Ras signaling and constitutively activated c-
myc. Interestingly, the minimum genetic alterations to induce a fibroblast to 
become cancerous include Ras activation, hTERT expression and SV40 large 
antigen, which targets the master tumor suppressors, p53 and pRb [59]. Linking 
oncogenic pathways to telomerase activation provides a mechanism by which an 
aspiring cancer cell can bypass many hurdles simultaneously. 
After hTERT transcription has been activated, molecular failsafes still remain 
to squelch the pro-cancer activities of a cancer cell apprentice. hTERT mRNA 
must be translated and the protein readied for its role. Reversible 
phosphorylation of hTERT protein regulates the protein's function, cellular 
localization and ultimately telomerase activity [60], Human TERT is 
phosphorylated by more than one kinase at different sites in the protein. A well-
described relationship between hTERT and a kinase is the association between 
hTERT and Akt (also known as protein kinase B). Akt is an important protein in 
the phosphatidylinositide-3 kinase (PI3K)-Akt-mammalian target of rapamycin 
(mTOR) signaling pathway that governs protein translation. Akt, a 
serine/threonine kinase, phosphorylates hTERT at Serine 824 (Ser 824) and 
Serine 227 (Ser 227) [61]; phosphorylation of either site upregulates telomerase 
activity. Protein kinase C (PKC) has also been to shown to induce hTERT 
expression and modulate its activities post-transcriptionally by phosphorylation 
[36, 62], 
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Likewise, hTERT phosphorylation is important in the nuclear localization of 
the protein where it may join hTERC and activate the telomerase holoenzyme 
[63]. Human TERT can only bind its nuclear translocator, nuclear factor (NF)-KP, 
in its phosphorylated form [64, 65], Upon localization in the nucleus, 
phosphorylated hTERT binds 14-3-3 signaling proteins that act to sequester 
hTERT in the nucleus where it may associate with the other components of the 
telomerase holoenzyme to perform its function to extend the telomeres [66], 
Tumor cells with high levels of telomerase activity contain phosphorylated forms 
of hTERT that are found mainly in the cell nucleus [67, 68], Conversely, protein 
phosphatase 2 A (PP2A) abrogates telomerase activity by dephosphorylating the 
protein. This maybe a direct dephosphorylation event or alternatively it could be 
a downstream effect of PP2A dephosphorylating Akt rendering it incapable of 
phosphorylating hTERT [69-71]. Heat shock protein 90 (Hsp90), a protein known 
to associate with both hTERT and Akt, also has an important role in telomerase 
activity. Hsp90 prevents PP2A from dephosphorylating Akt [69]. Further, Hsp90 
is necessary for assembly of the telomerase holoenzyme, and is itself regulated 
through phosphorylation [72]. Reactive oxygen species (ROS) have been shown 
to induce phosphorylation of hTERT Tyrosine 707 (Tyr707) via Src (sarcoma) 
kinase [73]. Tyr707 phosphorylation has the opposite effect of that observed 
with Ser824 phosphorylation; this event is critical for hTERT nuclear export, 
translocation back into the cytoplasm and loss of telomerase activity. Thus, 
nuclear localization is another level in the multistep regulation of telomerase 
activity. 
Human TERT protein levels are additionally regulated through the actions of 
the ubiquitin-protein ligase (E3 ligase) Makorin-1 (MKRN1) [74], MKRN1 
recognizes hTERT and targets it for degradation via the ubiquitin-26 S 
proteasome pathway (UPS). Hsp90 is thought to rescue hTERT from 
degradation by preventing the actions of MKRN1 [74]. While the mechanism is 
not understood currently, the association of Hsp90 with hTERT may prevent 
MKRN1 from recognizing hTERT as a substrate. MKRN1 levels dramatically rise 
when a cell enters the G1 state of the cell cycle, providing a possible link 
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between telomerase activity and the cell cycle [75]. Although MKRN1 is the only 
E3 ligase that has been identified currently, there may be other E3 ligases that 
target hTERT for degradation. 
Non-Telomeric Functions of Telomerase 
In addition to providing a cell with immortality, telomerase has a much larger 
role in cancer development. When hTERT is overexpressed in a variety of cells, 
the cells become resistant to apoptosis [76-79]. In fact hTERT blocks both the 
intrinsic and extrinsic apoptotic pathways [80-82], and is itself a target for 
caspase-6 and caspase-7 cleavage [83]. The mechanism by which hTERT 
blocks apoptosis is unclear; however it appears to inhibit an early step in the 
apoptotic pathway prior to caspase activation [84], 
Besides the anti-apoptotic functions of hTERT, telomerase is involved in 
multiple levels of DNA repair. hTERT and hTERC both have a role in regulating 
the ATM (ataxia telangiectasia mutated)-ATR (ataxia telangiectasia and Rad3-
related kinase) DNA damage pathway. hTERT upregulates ATM causing cell 
cycle arrest to allow DNA repair or apoptosis [85]; hTERC inhibits ATR, thereby 
preventing cell cycle arrest [86]. Cells that overexpress hTERT have 20-fold less 
spontaneous chromosome breaks and increased levels of ATP, possibly due to 
increased mitochondrial DNA protection [87], Many of the DNA damage 
response factors are dependent on ATP hydrolysis, including chromatin 
decondensation responsible for activating ATM, which results from a double-
strand break [88, 89]. Telomerase repairs these double-strand breaks by the de 
novo addition of telomeres in a process termed 'chromosome healing' [90], This 
extends the life of a cell with a defective genome, thus increasing the possibility 
of that cell becoming cancerous. 
Ectopic hTERT expression further revealed that hTERT is responsible for 
regulating nearly 300 genes that participate in functions such as cell cycle 
progression, apoptosis, metabolism and signaling [91]. Further, hTERT has been 
implicated in pRb hyperphosphorylation, causing unchecked cell cycle 
progression and providing a growth advantage for hTERT-overexpressing cells 
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Fig. 2. Proposed schematic representation of the hTERT-mTOR-RAPTOR 
complex in DU145 prostate tumor cells. The presence of mTOR in a complex 
with TERT provides compelling evidence for the mTOR-mediated control of 
telomerase activity. The arrows represent phosphorylation of the substrates 
by mTORCI. 
[92-94], Additionally, hTERT is responsible for the transcriptional activation of 
cyclin D1 [95], 
The cancerous phenotype associated with hTERT-overexpressing cells is 
exacerbated by the ability of hTERT to upregulate epidermal growth factor 
receptors (EGFRs) [96], EGFRs are responsible for multiple oncogenic signaling 
pathways. Increased numbers of cell surface receptor sensitizes a cell to low 
levels of growth factors. Thus under conditions of limited growth factors, 
signaling pathways deceive the cell that nutrients are ample. Cancer cells are 
known for their ability to survive in low nutrient environments by usurping EGFR 
signaling pathways. 
mTOR 
Hsp90, Akt, hTERT, p70 S6 kinase (S6K), and mTOR form a physical 
complex with one another (Fig. 2) [70], This complex provides compelling 
evidence mTOR-mediated control of telomerase activity. Through kinase 
cascades, mTOR regulates cell size, progression of the cell cycle, and cell 
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survival, arid is considered a master regulator of protein synthesis [97], mTOR, a 
serine/threonine kinase that is often dysregulated in cancer cells, is a member of 
the PI3K-related kinase (PIKK) family [98]. By nucleating two different functional 
multi-protein complexes, mTOR complex 1 (mTORCI) and mTOR complex 2 
(mTORC2), mTOR responds to nutrient, energy and oxygen stresses on the cell 
[99, 100]. The best characterized of these is the the mTORCI homodimer 
complex that consists of mTOR, accessory protein RAPTOR (regulatory-
associated protein of mTOR), mammalian lethal with Sec13 protein 8 (mLST8) 
(also known as G|3L), PRAS40 (proline-rich AKT substrate 40 kDa), and DEP-
domain-containing mTOR-interacting protein (DEPTOR) (Fig. 3) [99]. mTOR can 
alternatively associate with the complex involving RICTOR (rapamycin-
insensitive companion of mTOR), mLST8, DEPTOR, PROTOR (protein observed 
with RICTOR), and mSIN1 (mammalian stress-activated protein kinase 
interacting protein); this complex is termed mTORC2 (Fig. 3) [99]. In addition to 
mTORCI mTORCI 
Fig. 3. Schematic representation of the mTORCI and mTORC2 complexes. 
mTOR is known to nucleate two distinct protein complexes. The mTORCI 
complex consists of mTOR, RAPTOR, PRAS40, DEPTOR, and mLST8. 
mTORC2 consists of mTOR, RICTOR, mSIN1, DEPTOR, PROTOR, and 
ml_ST8. Despite having a few proteins in common, these complexes are 
known to behave very differently from one another. 
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being necessary for the catalytic activities of mTOR, both RICTOR and RAPTOR 
help to recruit downstream targets to the complex [101]. mTORCI, touted for its 
nutrient sensing abilities, is associated with the predominant pathway by which 
mTOR controls cell growth and proliferation, the PIK3-Akt-mTOR pathway. It is 
now understood that mTORC2 has a role in this pathway by activating Akt 
through phosphorylation, creating a positive feedback loop [102], mTORC2 is 
also known for its ability to direct actin remodeling [100]. The well-established 
functions of mTOR are due to mTORCI, as mTORC2 functions are just now 
beginning to be elucidated [103]. 
Upstream Regulation of mTOR 
The PI3K-Akt-mTOR pathway is an important mechanism that allows 
communication between cellular and intracellular proteins responsible for growth 
and proliferation. When insulin binds its receptor on the cell membrane surface, 
a kinase cascade is initiated. The binding event signals insulin receptor 
substrate 1 (IRS1) to the intracellular portion of the receptor [104], IRS1 then 
activates the first kinase in this pathway, PI3K, which recruits Akt to the 
intracellular portion of the cell membrane [104-107]. Akt is then activated 
through both phosphoinositide-dependent protein kinase I (PDK1) and mTORC2. 
Akt in turn phosphorylates the GTPase activating protein (GAP)-tuberous 
sclerosis 2 (TSC2)-thereby deactivating the protein. In the absence of a growth 
factor such as insulin, the active TSC2 forms a complex with TSC1 that 
accelerates the exchange of Rheb (Ras homolog enriched in brain)-GTP 
(guanosine triphosphate) to Rheb-GDP (guanosine diphosphate). Rheb must be 
in the GTP form in order to directly stimulate mTORCI [104, 105]. As a 
consequence of Akt phosphorylation, TSC2 is deactivated, thereby allowing 
mTORCI activation through Rheb-GTP. Akt also phosphorylates PRAS40, an 
inhibitor of mTORCI, therefore deactivating it [108]. Although PRAS40 is a 
known binding partner of mTORCI, in the absence of insulin, PRAS40 functions 
to inhibit Rheb activation of mTORCI [108]. 
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Translational Control: Regulation of elF4 and p70 S6 Kinase 
Fig. 4. The mTOR pathway. mTOR is considered a master regulator of 
protein translation. This pathway depicts the numerous proteins upstream 
and downstream of mTOR, which ultimately determines when cap-
dependent translation is turned on or off. Illustration from Cell Signaling 
Technology, Inc., 2003-2010. 
Down-stream Targets of mTOR 
Mitogenic activation of mTORCI increases cap-dependent translation 
initiation through phosphorylation of S6K and 4E-binding protein 1 (4E-BP1) (Fig. 
4). mTORCI activates S6K through the phosphorylation of specific sites on the 
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protein. Only the active or phosphorylated form of S6K can act as a kinase and 
phosphorylate S6, a ribosomal protein. S6 activation is necessary for translation 
of ribosomal proteins. Through a negative feedback loop, S6K also 
phosphorylates IRS1, therefore deactivating the protein necessary to initiate 
PI3K-Akt-mTOR pathway [109]. S6K also activates eukaryotic initiation factor 
(elF) 4B, a protein responsible for activating elF4A, a helicase necessary to 
unwind the 5' untranslated region (UTR). In addition, S6K inhibits programmed 
cell death protein 4 (PDCD4), a protein that inhibits elF4A [110]. mTORCI also 
acts as a kinase that directly phosphorylates 4E-BP1, an inhibitor of translation, 
resulting in dissociation of elF4E. This allows the mRNA cap-binding protein to 
associate with the scaffold protein elF4G [111]. The association of activated 
elF4A with elF4E and elF4G completes formation of the 7-methylguanosine 
triphosphate (m7GpppX) cap-binding complex termed elF4F [112]. Binding of 
elF4F to the 5' cap of mRNA is followed by circularization of the mRNA, a 
process that occurs via interactions between elF4G and the poly-A binding 
protein (PABP) [113]. The 43S complex, consisting of the 40S ribosomal 
subunit, elF2/GTP/Met-tRNAi, and elF3, binds to elF4F via interactions between 
elF3 and elF4G forming the preinitiation complex [111]. This complex begins 
scanning the mRNA in a 5' to 3' direction from the mRNA cap. Once a 
translation initiation codon or AUG with the optimal consensus sequence is 
located, the pre-initiation complex is released and an initiating methionine is 
inserted into the aminoacyl site formed by association of the 60S ribosomal 
subunit with the 40S ribosomal subunit to form an 80S ribosomal complex. 
Subsequent elongation of the protein occurs though translocation of the nascent 
peptide to the peptidyl site of the 80S complex and formation of peptide bonds 
[111]. 
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Fig. 5. How cellular stressors regulate mTOR activation. Activation of mTOR 
by growth factors is depicted as a black line. mTOR inhibition by a protein is 
depicted by a grey line. Pathways that have not been confirmed as a direct 
association between the protein and mTOR is shown as a dotted line. 
Importantly, elF4E is the rate-limiting component of the translation initiation 
complex [114]; its release from 4E-BP1 due to mTORCI activation, controls 
protein translation. mRNAs with 5'-UTRs that are G-C rich have substantial 
secondary structure, and cannot compete for elF4E as well as mRNAs without 
stable 5-UTR secondary structure [115-117]. Consequently, free elF4E levels 
are tightly regulated through mitogenic activation of the mTOR signal 
transduction pathway [118]. Due to the ability of mTORCI to inhibit an inhibitor 
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(4E-BP1) and activate a protein crucial to translation initiation (S6K), mTORCI is 
a master regulator of protein synthesis [119]. 
In addition to its well-established function in modulating translation initiation, 
mTOR is responsible for cell growth regulation, transcriptional control, and 
autophagy repression [105]. mTORCI mediates cell cycle regulation by 
increasing elF4E levels sufficiently to initiate cap-dependent translation of cyclin 
D1 mRNA [120]. Conversely, in cells where mTORCI is inactivated, translation 
initiation of cyclin D1 mRNA is suppressed sufficiently to arrest the cell in G1 
[120]. The mTORCI pathway also controls cell size and glucose homeostasis 
apparently through the activation of S6K, although the mechanisms are not yet 
clear [121]. S6K activation also increases the levels of survivin, an inhibitor of 
apoptosis [122], mTOR-mediated autophagy repression is a result of a direct 
interaction of mTOR with the ULK (Unc-51-like kinase 1) complex necessary to 
initiate autophagy [105], With assorted downstream targets of mTOR whose 
activation or repression can result in either survival or cell death, it is imperative 
to properly regulate the mTOR pathway to preserve normal cellular homeostasis. 
Cellular mTOR Inhibition 
Diverse cellular stressors inhibit the mTOR pathway through various 
mechanisms (Fig. 5) [97], Protein translation occurs at a high adenosine 
triphosphate (ATP) cost for the cell. Therefore, shutting it down when the cell is 
stressed is imperative. DNA damage is one such cellular stress that activates 
both p53 and Redd1/RTP01 [123]. Through downstream signaling, both of these 
proteins activate TSC 1/2 and inhibit mTOR via Rheb [124], Hypoxia is a well 
characterized stressor that signals activation of BCI2/adenovirus E1B 19 kDa 
protein-interacting protein 3 (BNIP3), promyelocytic leukemia tumor suppressor 
(PML), and Reddl via induction of HIF-1 [125]. BNIP3 inhibits Rheb 
independently of TSC 1/2; PML directly inhibits mTOR [125], Hypoxia and 
glucose derivation lead to low ATP, a signal that activates 5'AMP-activated 
protein kinase (AMPK) [126]. AMPK inhibits mTOR directly and activates TSC 
1/2 [126], Glucose deprivation is third type of stress that activates Reddl, 
making Reddl a critical activator of TSC 1/2. Interestingly, it has been shown 
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that cigarette smoke can also induce Reddl [127]. Amino acid deprivation 
inhibits two activators of mTOR, GTPase Rag (Ras related GTPase) and Map4k3 
(mitogen-activated protein kinase kinase kinase kinase 3) [128], When active, 
Rag serves to bind RAPTOR and translocate mTORCI to the surface of an 
endomembrane compartment, serving along with Rheb to activate mTORCI 
[129]. The redundancy in pathways mediating mTOR inhibition highlights the 
importance of maintaining protein only under ideal cellular conditions. 
mTOR and Cancer 
The mTOR pathway is often constitutively active in cancer cells, leading to 
aberrant protein translation, cell growth, and proliferation. The tumor suppressor, 
phosphatase and tensin homolog (PTEN), is commonly deleted or truncated in 
endometrial, breast, prostate and ovarian cancers leading to overexpression of 
the PI3K-Akt-mTOR pathway [130], A commonly observed mutation in PIK3CA 
in breast, colorectal, and endometrial cancers results in overexpression of Akt 
and increased transformation in vitro and in vivo [131]. The AKT1 gene may also 
be amplified causing it to be overexpressed in some tumor cell types. AKT1 
mutations have been shown to constitutively activate the protein, as seen in 
some breast, colorectal and ovarian cancers [132-134], Enhanced expression of 
the downstream target of mTORCI, elF4E, by gene amplification is also 
regularly observed in tumor cells, leading to increased protein translation [135], 
elF4E-overexpression is an independent biomarker of cancer recurrence in head 
and neck cancers [136], The array of mutations identified that lead to mTORCI 
pathway upregulation in numerous diverse cancers support the role of mTOR as 
an attractive anti-cancer target. 
Rapamycin 
The classical mTOR inhibitor is the macrolide antibiotic, rapamycin (Fig. 6 
(a)). The vast array of mTORCI functions were revealed through the use of 
rapamycin. Rapamycin was discovered in Streptomyces hygroscopicus in the 
soil on Easter Island in the 1970s [137]; it was not until the 1990s that the cellular 
target of this drug, mTOR, was uncovered [99], Rapamycin binds to the 12 kDa 
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immunophilin FK506-binding protein (FKBP12), forming a drug-receptor complex, 
which then binds to mTOR. This process weakens the association of mTOR 
with RAPTOR, thus inhibiting the kinase activity of mTOR [138-140]. Although 
mTORC2 is considered rapamycin-insensitive, it has been shown that prolonged 
treatment with rapamycin does inhibit mTORC2 assembly [141]. 
Cellular treatment with rapamycin causes decreased phosphorylation of 4E-
BP1, therefore reducing the level of free elF4E for translation initiation [142], 
Rapamycin likewise attenuates the phosphorylation of S6K and S6 ribosomal 
protein [142]. It has been shown that rapamycin at 10 nM at 4 hr, a clinically 
relevant concentration [143], is capable of inhibiting the mTORCI pathway, thus 
impeding cellular proliferation, growth and translation initiation [144, 145], 
Analogs of rapamycin ('rapalogs') have been approved for use in several forms 
of metastatic cancers and continue to be evaluated in Phase III solid tumor 
studies. 
An mTOR and telomerase liaison 
An association between mTOR and telomerase activity was first proposed 




Fig. 6. Biochemical structures of rapamycin and perillyl alcohol, (a) 
Rapamycin; (b) Perillyl alcohol. www.SigmaAldrich.com 
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at high concentrations (100 - 1000 nM) and long treatment conditions (48 to 72 
hr), inhibited both telomerase activity and hTERT mRNA levels [146, 147]. 
Effects on hTERT mRNA levels were somewhat surprising based on the known 
cellular target of mTOR—protein translation. It should be pointed out that the 
maximum tolerated dose of oral rapamycin administered to adult cancer patients 
on a daily basis has been reported at ~6 mg/d, which results in a maximal 
plasma concentration of ~22 nM [143], hTERT co-immunoprecipitates with 
mTOR, S6K, Hsp90 and Akt, suggesting that these proteins form a physical and 
functional complex [70]. Bu et al. also proposed in 2007 [148] that mTOR 
signaling was 'coupled' to telomerase regulation. In contrast to the above two 
studies, Bu et al. showed that rapamycin (10 nM) had no effect on the hTERT 
promoter, but that hTERT protein levels were decreased; they concluded that 
hTERT regulation by rapamycin was post-transcriptional [148]. Researchers and 
clinicians may be able to take advantage of this relationship between mTOR and 
telomerase for effective combination therapy and/or cancer chemoprevention. 
Bu et al. (2007) also noted synergy in regards to down-regulation of telomerase 
activity between rapamycin and fluorouracil treatment of hepatocarcinoma cells 
in culture [148], 
In addition, because telomerase activation/de-repression is an early event 
in cancer cell formation, the ideal chemopreventive would be present and active 
before cancer is detectable. Rapamycin itself has been touted as a new potent 
cancer chemopreventive agent [149, 150], but grave concerns about toxic side 
effects (immunosuppression), safety (feedback activation of Akt and enhanced 
tumorigenesis) and pharmacokinetic issues temper enthusiasm for this approach 
[151, 152]. The potential effectiveness of plant-derived dietary factors with 
relatively low acute toxicity [153] contrasts to that of rapamycin; consequently 
phytochemicals may represent a more feasible and effective method for cancer 
prevention. As described below, isoprenoids have been reported to modulate 
either mTOR signaling or telomerase activity. These data reported in this study 




Isoprenoids (also designated as terpenes), found widely in fruits and 
vegetables, represent the largest group of natural products with -25,000 
structures reported [154, 155], and are recognized for their ability to suppress 
carcinogenic processes in vivo and in vitro [153, 156-158]. Isoprenoids are 
small, lipophilic products of the plant mevalonate biosynthetic pathway [153], 
Isoprenoids are so-named because of their basic chemical structure consisting of 
multiples of an isoprene (5-carbon) subunit: monoterpenes consist of C10, 
sesquiterpenes, C15; diterpenes, C20 and others. In plants they function as 
repellents, attractants or toxins, and provide resistance to aphid infestations or 
fungal- and bacterial-caused diseases [154], Isoprenoids are relatively non-toxic 
in human studies even at high doses [159], 
Perillyl alcohol, a structurally simple monoterpene, is found predominantly in 
oils from cherries, cranberries, lavender, celery seed and spearmint (Fig. 6 (b)) 
[79, 160], Perillyl alcohol and other related terpenes, such as farnesol and 
geraniol, exhibit chemopreventive and cytotoxic activity against a wide variety of 
cancer cell lines [153, 156, 158, 161], Perillyl alcohol was found to act uniquely 
and mechanistically on protein translation through modulation of mTOR signaling 
pathway [145]. It specifically decreases 4E-BP1 phosphorylation and disrupts 
the elF4F 5'- cap-binding complex [144, 145]. While perillyl alcohol has been 
shown to suppress the mTOR pathway, the mechanism appears to be distinct 
from that for rapamycin. In addition to the mTOR pathway, perillyl alcohol has 
the ability to inhibit other pathways associated with the cancer phenotype, such 
as cell growth, pRB phosphorylation and Cdk phosphorylation [162-165]. Perillyl 
alcohol can also counteract proliferation and initiates apoptosis and G1 arrest 
[165-170], Although a small, natural compound, perillyl alcohol is becoming well-
established as a cancer chemopreventive agent [153, 158]. 
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Rationale of Study and Specific Aims 
Prostate cancer is a leading cause of cancer death among men, second 
only to lung cancer. One in six males will be diagnosed with prostate cancer 
during their lifetime, with no effective cure available for those with advanced 
stages of the disease. hTERT, the limiting factor for telomerase activation, is de-
repressed in prostate cancer cells and in part makes these cells immortal. It has 
been reported that hTERT forms a functional complex with mTOR, S6K, Hsp90 
and Akt in activated natural killer cells (NK). mTOR is a master regulator of 
protein translation through its ability to release the rate limiting component of 
cap-dependent translation, elF-4E, from 4E-BP1. The presence of mTOR in 
association with hTERT strongly signifies mTOR's involvement in regulating 
telomerase activity. The macrolide rapamycin effectively treats hormone-related 
cancers through its modulation of the mTOR pathway. A plant-derived 
isoprenoid perillyl alcohol also suppresses mTOR signaling; its mechanism of 
inhibition appears to be similar but distinct from that for rapamycin. Perillyl 
alcohol is potentially more effective at preventing prostate cancer than is 
rapamycin due to its small size, lipophilic nature and relatively low toxicity. 
Recent studies have shown that rapamycin at high concentrations and long 
incubations inhibits telomerase activity and hTERT mRNA levels. Currently, it is 
unknown if perillyl alcohol also modulates telomerase activity. Thus perillyl 
alcohol may be important clinically due to the documented immunosuppressive 
toxicity of rapamycin in cancer patients. Therefore, perillyl alcohol-mediated 
inhibition of hTERT represents a potential cancer chemopreventive or adjuvant 
for therapy. 
Our long-term goal is to understand the mechanism by which isoprenoids 
are effective as chemopreventives. The objective of this research is to explore 
the relationship between perillyl alcohol, telomerase function and the mTOR 
pathway. The central hypothesis is that perillyl alcohol regulates hTERT at the 
translational and post-translational levels via its effects on the mTOR pathway. 
The hypothesis is supported by studies demonstrating similarity between the 
mechanisms of action of rapamycin and perillyl alcohol, and the known inhibitory 
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relationship between rapamycin and telomerase activity. The rationale 
supporting the proposed research is that elucidating novel mechanisms by which 
perillyl alcohol inhibits prostate cancer cell proliferation will enhance exploitation 
of this agent as a chemopreventive for prostate cancer. The central hypothesis 
will be tested and the objective of this proposal met through the following three 
specific aims: 
Specific Aim 1. Establish the translational and post-translational effects of 
perillyl alcohol treatment on hTERT regulation in cultured human 
prostate cancer cells. Specifically, DU145 and PC3 cells will be treated 
with solvent, perillyl alcohol or rapamycin as a positive control, and: 
A. Telomerase activity assessed using real-time polymerase chain 
reaction telomeric repeat amplification protocol (RTQ-TRAP) as 
well as non-denaturing polyacrylamide gel electrophoresis (PAGE); 
B. SDS/PAGE and western blots performed to detect potential 
modulation of hTERT protein levels, phosphorylation status, cellular 
location and degradation; and 
C. Co-immunoprecipitation with a RAPTOR or mTOR antibody, silver 
stained gel analysis, and western blots carried out to establish the 
presence of co-precipitating proteins in the hTERT-mTOR-
RAPTOR protein complex in untreated cells and possible disruption 
of the complex by perillyl alcohol and/or rapamycin. 
Specific Aim 2. Define the transcriptional effects, if any, of perillyl alcohol 
treatment on hTERT regulation in prostate cancer cells. DU145 and 
PC3 cells will be treated with solvent, perillyl alcohol or rapamycin as a 
positive control, and: 
A. Real-time reverse transcriptase-polymerase chain reaction (real­
time RT-PCR) utilized to measure isoprenoid effects on hTERT 
mRNA levels. 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-
CoA) reductase mRNA will be included as a control; results will be 
interpreted using the AA Ct method. 
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Specific Aim 3. Examine telomerase activity, TERT mRNA and TERT 
protein levels in cells that over-express eukaryotic initiation factor 4E 
(elF4E)-the rate-limiting factor for cap-dependent translation regulated 
by mTOR. Immortalized Chinese hamster ovary (CHO) cells 
transfected with an e/F4£-expressing vector or a control vector will be 
treated with solvent, perillyl alcohol or rapamycin as a positive control 
and: 
A. SDS/PAGE and western blots performed to study the effect of 
elevated elF4E on TERT, Akt, S6K, and 4E-BP1 protein levels and 
the phosphorylation status of Akt, S6K, and 4E-BP1; 
B. Real-time RT-PCR conducted to assess the consequence of 
amplified elF4E on TERT mRNA. Actin mRNA will be included as a 
control; and 
C. RTQ-TRAP exploited to measure alterations in telomerase activity 
when elF4E is over-expressed. 
SIGNIFICANCE 
The proposed research is innovative, because a relationship between 
telomerase activity, hTERT and perillyl alcohol has not been explored or 
exploited previously. Our study is projected to first: identify and establish a 
translational and/or post-translational inhibitory relationship between perillyl 
alcohol and hTERT. This finding will allow us to determine the mechanism by 
which perillyl alcohol can be used as a cancer chemopreventive. Secondly, we 
expect to find that perillyl alcohol down-regulates hTERT through the mTOR 
pathway. With this knowledge perillyl alcohol may be used as an adjuvant to 
current chemotherapy regiments that do not target the mTOR pathway. By using 
a biologically relevant concentration of rapamycin for a reasonable period of time 
as a control, we will be able to determine the direct effects of mTOR inhibition on 
telomerase activity. The expected outcomes are foreseen to have an important 
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positive health impact because these findings will lead to novel cancer 
therapeutics/adjuvants and greatly advance the field of chemopreventives. 
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CHAPTER II 
THE ISOPRENOID PERILLYL ALCOHOL INHIBITS TELOMERASE 
ACTIVITY IN PROSTATE CANCER CELLS 
INTRODUCTION 
Nutritional epidemiologists emphasize that diet has a major role in the 
incidence and progression of prostate and other types of cancer [39, 153, 158, 
171]. Isoprenoids (also referred to as terpenes), found widely in fruits and 
vegetables, represent the largest group of naturally occurring organic chemicals 
with ~25,000 structures reported [155], and are recognized for their ability to 
suppress carcinogenic processes in vivo and in vitro [172]. Perillyl alcohol is a 
small lipophilic isoprenoid found predominantly in oils from cherries, cranberries, 
lavender, celery seed and spearmint [79, 160], Perillyl alcohol and other related 
terpenes, such as famesol and geraniol, exhibit chemopreventive and cytotoxic 
activity against a wide variety of cancer cell lines [153, 156, 158, 161]. 
Additionally, perillyl alcohol alone or included as an adjuvant inhibited various 
tumor xenografts in mouse models including human pancreatic cancer cells [172-
175]. Previous studies in our lab demonstrated that perillyl alcohol acts uniquely 
and mechanistically on protein translation through modulation of the mammalian 
target of rapamycin (mTOR) signaling pathway [145], 
mTOR, a serine/threonine protein kinase, is a critical component of the 
phosphoinositide 3-kinase (PI3K)/Akt pathway. Through kinase cascades, 
mTOR regulates cell size, progression of the cell cycle and cell survival [119], 
mTOR protein exists in two functional complexes: mTORCI and mTORC2. 
mTORCI regulates protein translation through phosphorylation and activation of 
p70 S6 kinase (S6K) and 4E-binding protein 1 (4E-BP1). Only the active form of 
S6K can subsequently phosphorylate S6, a ribosomal protein, which is 
necessary for ribosome assembly and protein translation. Phosphorylation of 
4E-BP1, an inhibitor of translation, causes it to dissociate from eukaryotic 
initiation factor 4E (elF4E) allowing translation to begin. Due to its ability to 
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inhibit an inhibitor (4E-BP1) and activate a protein crucial to translation initiation 
(S6K), mTORCI is a master regulator of protein synthesis [119]. 
The classical mTOR inhibitor is the macrolide, rapamycin. Rapamycin 
treatment causes decreased phosphorylation of 4E-BP1. Unphosphorylated 4E-
BP1 binds elF4E efficiently and reduces cellular levels of elF4E available for 
formation of the m7GpppX cap-binding complex-elF4F. Rapamycin likewise 
reduces the phosphorylation of S6K and S6 ribosomal protein [142]. Perillyl 
alcohol displays similar properties to rapamycin, but is distinct, in that it 
suppresses 4E-BP1 phosphorylation in human prostate and colon tumor cells via 
mTORCI, with a similar or greater effect than that observed with rapamycin as 
detected by western blotting [144, 145], Perillyl alcohol also disrupts the 
m7GpppX cap binding complex, elF4F, by suppressing interaction of elF4E with 
elF4G [144, 145], 
Recently, both mTOR and S6K were found to co-immunoprecipitate with 
human telomerase reverse transcriptase (hTERT), Hsp90 and Akt suggesting 
that these proteins form a physical and functional complex [70], hTERT is one of 
three components of telomerase, a ribonucleoprotein complex responsible for 
adding 6 base pair (bp) repeats to the end of a chromosome to prevent loss of 
DNA during replication. This action is necessary due to the fundamental 
limitation of polymerization at chromosome ends. hTERT, the rate limiting 
enzymatic portion of telomerase, is a potential candidate for cancer therapy due 
to its absence in most normal somatic cells, but its re-activation in many tumor 
cells. Telomerase activation is an early and key event in the creation of tumor 
cells, and as such, is an important target in cancer prevention. The inclusion of 
mTOR and S6K in the hTERT complex is compelling evidence to support mTOR-
mediated control of telomerase activity, and as such, we hypothesize that 
isoprenoids, such as perillyl alcohol, suppress telomerase activity. The effects of 
perillyl alcohol on telomerase activity are examined in this work. 
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MATERIALS AND METHODS 
Cell lines and cell culture 
Human prostate cancer cell lines PC3 and DU145 (American Type Culture 
Collection, Manassas, VA) were maintained at 37°C in a humidified incubator 
with 5% C02 in RPMI-1640 medium supplemented with 10% fetal bovine serum, 
1X glutamine and 1X penicillin/streptomycin. Growth medium was changed every 
other day. 
Drug treatments 
Perillyl alcohol (Sigma-Aldrich, St. Louis, MO) was prepared in 100% 
ethanol; rapamycin (Cell Signaling Technology, Danvers, MA) was dissolved in 
100% dimethyl sulfoxide (DMSO) [145], PC3 and DU145 cells were plated at a 
concentration of 5x105 cells per 60 mm plate in 3 mL medium and allowed to 
attach overnight. Cells were then treated with one of the following: 400 pM 
perillyl alcohol for 16 hr, 10 nM rapamycin for 4 hr, 0.1% DMSO for 4 hr or 0.1% 
ethanol for 16 hr as described by Peffley et al. [145]. In separate experiments, 
shorter incubations with either drug were also conducted to establish a time 
course of possible effects. 
Protein extraction for telomerase activity 
Cells were harvested using trypsin-EDTA (Gibco/lnvitrogen, Carlsbad, CA) 
and then pelleted by centrifugation (500 x g) for 8 min. Cell pellets were washed 
with phosphate-buffered saline (PBS) and centrifuged again. Protein lysates 
were obtained by resuspending PC3 or DU145 cells in 200 pL of ice-cold 1X 
CHAPS lysis buffer per 1x106 cells. The CHAPS lysis method was modified from 
that presented in Hou et al. and others [176-179]. CHAPS lysis buffer consisted 
of 0.5% 3-[(3-Cholamidopropyl)dimethylammonio]-l-propanesulfonic acid 
(CHAPS), 10 mM Tris-HCI, pH 7.5, 1 mM MgCI2, 1 mM ethylene glycol 
tetraacetic acid (EGTA), and 10% glycerol. RNase inhibitor (New England 
Biolabs, Beverly, MA) (final concentration of 10 units/mL) and B-mercaptoethanol 
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(BME) (final concentration of 5 mM) were added just prior to use. Cell lysates 
were incubated at 4°C for 30 min and then centrifuged at 12000 x g for 30 min at 
4°C. The supernatant was collected, protein concentration was interpolated 
using a Bradford assay and extracts were stored at -86°C. 
RTQ-TRAP assay 
Telomerase activity was detected by performing real-time quantitative 
telomerase repeat amplification protocol (RTQ-TRAP) as derived from a protocol 
described by Hou et al. [178]. In detail, each 25 pL RTQ-TRAP reaction 
contained: 1X SYBR Green Master mix (50 mM KCI, 20 mM Tris-HCI, pH 8.4, 0.2 
mM each dNTP, 3 mM MgCI2, iTaq DNA polymerase at 0.05 units/pL) (Bio-Rad, 
Richmond, CA), 10 mM EGTA, 0.2 pg T4 gene protein (New England Biolabs), 
0.35 pM TS primer (5-AATCCGTCGAGCAGAGTT-3') (Tm 53.6°C) and 0.35 pM 
ACX primer [5'-GCGCGG(CTTACC)3 CTAACC-3T (Tm 66.4°C) [180], and 2.5 pg 
of protein extract. Primers were purchased from Integrated DNA Technology 
(IDT, Coralville, IA). All samples were analyzed in duplicate or triplicate in a 96-
well plate on a Bio-Rad CFX96 thermal cycler, and 1X CHAPS buffer was 
included as a negative control. Reactions were incubated at 25°C for 20 min to 
allow for elongation of the TS primer by cellular telomerase. The PCR protocol 
began with a 95°C hot start to activate Taq polymerase, followed by 40 cycles at 
95°C for 20 s, 50°C for 30 s, 72°C for 90 s [178], ending with a melt curve 
protocol. Telomerase activity was comparatively assessed based on threshold 
cycles (CT) [178]. Cr values greater than 35 were considered false positives due 
to primer dimers. Inhibition of telomerase activity was determined as follows: 
(Cj treatment) - (CT control) = ACT 
(1 / 2ACT) X 100 = % ACTIVITY REMAINING 
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RTQ-TRAP product analysis by native Polyaerylamide Gel Electrophoresis 
(PAGE) 
TRAP products were also analyzed on a non-denaturing 10% 
polyacrylamide mini-gel (8.3 x 6.4 x 0.1 cm) (Bio-Rad) in 0.5X Tris-borate-EDTA 
(TBE) (50 mM Tris, pH 8.4, 44.5 mM boric acid, 0.5 mM EDTA) buffer. The 
protocol was derived from that presented by Dikmen et al. [181]. DNA 100-bp 
ladder markers (Bio-Rad) were included for size references. DNA products (~20 
pL) were re-suspended 1X Nucleic Acid Sample Loading Buffer (Bio-Rad) and 
electrophoresed for 30 min at 200 volts. Gels were then stained with SYBR® 
Green I Nucleic Acid Stain (Invitrogen) per manufacturer's suggestions. In most 
cases gels were additionally stained with 0.01 mg/mL ethidium bromide for 10 
min to obtain the clearest picture. Gels were photographed on a Kodak image 
station. 
RNA extraction and quantification 
Total cellular RNA was isolated using PureZOL™ (Bio-Rad) according to the 
manufacturer's protocol. RNase-free-DNase I digestion (50 units) (Roche 
Applied Science, Indianapolis, IN) was also performed. RNA quantification was 
determined by UV absorbance on a BioPhotometer Plus (Eppendorf®, Hamburg, 
Germany). RNA intactness was assessed by analyzing 28S and 18S subunits of 
ribosomal RNA by ethidium bromide 2% agarose gel analysis. 
hTERTmRNA levels 
Expression of hTERT mRNA was detected using real-time RT-PCR. One 
pg of purified cellular RNA from untreated and treated cells was reverse 
transcribed into cDNA using iScript (Bio-Rad) at 42°C for 30 min in the presence 
of random hexamers and oligo(dT), Moloney murine leukemia virus reverse 
transcriptase and RNasin. Analysis of the expression of hTERT mRNA was 
performed by real-time PCR amplification using the Bio-Rad CFX96 thermal 
cycler. PCR primer sets for hTERT cDNA (GenBank ID: AF015950) and Homo 
sapiens 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase cDNA (GenBank 
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ID: NM_000859) sequences were optimized using Beacon Designer software 
(PREMIER Biosoft International, Palo Alto, CA). PCR efficiencies for each 
primer set were determined in triplicate by a dilution series of the cDNA template. 
A master mix contained 1X SsoFast EvaGreen (Bio-Rad), 0.5 |JM of each 
forward and reverse primer, and 1.5 |jl of cDNA per reaction. A 140-bp hTERT 
fragment was amplified with the primer pair 5'-GAGTGTCTGGAGCAAGTTG-3' 
(Tm 52.6°C, located in exon 3) and 5-GGATGAAGCGGAGTCTGG-3' (Tm 
53.6°C, located in exon 4) (IDT). A 122-bp reductase amplicon was amplified as 
an internal control using the primer pair 5'-TGCAGAGCAATAGGTCTTGGTG-3' 
(Tm 58.1°C, spans exons 13 and 14) and 5'-TCGAGCCAGGCTTTCACTTC-3' 
(Tm 57.3°C, located in exon 14). The real-time PCR program used was 95°C for 
30 s, followed by 35 cycles at 98°C for 30 s, 65°C for 30 s, ending with a melt 
curve analysis step where the temperature was reduced to 65°C, then increased 
to 95°C in 0.2°C increments every 5 s. The AACT method was used to 
comparatively analyze the data as described in Livak and Schmittgen [182], 
Protein extraction and immunoblotting 
The protocol described by Peffley et al. [145] was used with minor changes. 
Briefly, cells were plated at 3x106 per 100 mm culture dish and allowed to attach 
for 24 hr before treating with perillyl alcohol or rapamycin as above. Cells were 
lysed in 250 RIPA lysis buffer containing fresh 1X Complete protease inhibitor 
cocktail (Roche Applied Science), 1 mM Na3V04 and 1 mM NaF, and protein 
concentrations were determined by a Bradford assay. Protein levels were 
assessed by western blotting according to [145] with some modifications. Thirty 
to 50 Mg total protein per well were loaded on a 4-15% polyacrylamide TGX mini-
gel (Bio-Rad) and resolved by electrophoresis in 1X Tris-glycine-SDS (0.025 M 
Tris, 0.192 M glycine, 0.1% SDS, pH 8.3) for 30 min at 200 volts. Electrophoretic 
transfer onto polyvinylidene fluoride (PVDF) membrane was performed in 1X 
Tris-glycine buffer. Membranes were blocked in protein-free blok-CH™ buffer 
(Millipore, Temecula, CA) for 1 hr at room temperature and then incubated with 
gentle rocking in one of the following primary antibodies: mouse monoclonal anti-
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elF4E (1:250, clone P2, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), rabbit 
polyclonal anti-hTERT (1:1000; clone Y182, Millipore), rabbit polyclonal anti-
MKRN1 (Makorin-1) (1.25 MO^L, Abeam, Inc., Cambridge, MA), mouse 
monoclonal anti-alpha-tubulin (1:250; clone 10D8, Santa Cruz Biotechnology, 
Inc.), or rabbit polyclonal anti-TERT (phospho S824) (1:1000, Abeam, Inc.). 
Incubations were conducted overnight at 4°C and followed by extensive 
washes in 1X Tris-buffered saline (TBS)-Tween 20 (0.02M Tris, pH 7.4, 0.15 M 
NaCI, 0.05% Tween 20). HRP-conjugated secondary antibodies (goat anti-rabbit 
or goat anti-mouse [Santa Cruz Biotechnology, Inc.]) were diluted 1:5000 in blok-
CH™ buffer and incubated for 1 hr at room temperature along with 1 pL 
StrepTactin-HRP (Bio-Rad) per 10 ml. solution to visualize Precision Plus protein 
standards (Bio-Rad). HeLa nuclear extract (25 pg, Millipore) was used a positive 
control for MKRN1 detection. Specificity of the hTERT antibody was confirmed 
by comparing band patterns from DU145 cell lysates (with re-activated TERT) to 
that of normal human XP30RO fibroblasts (TERT negative) (Coriell Institute, 
Camden, NJ). Anti-actin antibody (1:1000; clone H-300; Santa Cruz) was 
included to confirm equal protein amounts in both lanes. Subsequent membrane 
washes were as described [145] and then blots were incubated for 5 min in 
Immun-Star™ HRP detection system (Bio-Rad) before capturing images on a 
Kodak Image Station. Densitometric analysis of protein bands was conducted 
using Kodak Molecular Imaging Software version 4.0.4. Band intensities for 
proteins of interest were compared relative to the levels of elF4E, which do not 
change in response to the above treatments and provide a control for loading 
and transfer onto PVDF membranes [145]. 
Cytoplasmic and nuclear lysates 
DU145 cytoplasmic and nuclear lysates were obtained using NE-PER® 
Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, Rockford, IL) 
according to manufacturer's instructions. Briefly, 3x106 DU145 cells were 
harvested using trypsin-EDTA, centrifuged at 500 x g for 5 min, rinsed with PBS 
and then centrifuged again. The supernatant was removed, and 300 pL of ice-
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cold CER I solution was added. After the appropriate vortexing and incubation 
steps, 16.5 pL of CER II solution was added. Subsequent vortexing and 
centrifugation were performed following the manufacturer's protocol, resulting in 
a supernatant (cytoplasmic fraction) of DU145 cells and an insoluble pellet. The 
insoluble pellet was suspended in 100 pL of NER, vortexed and centrifuged, 
which produced a nuclear fraction in the supernatant. 
Statistical analysis 
All experiments were conducted three to five times with sub-sampling of 
each independent quantitative experiment. Data are expressed as a mean +/-
standard deviation. Data were analyzed using Model I ANOVAs with SPSS 
version 19.0. The relationship of interest was perillyl alcohol versus control and 
rapamycin versus control; therefore, Dunnett's test was used as a follow-up to 
determine statistical significance of the results. 
RESULTS 
Telomerase activity is decreased by both perillyl alcohol and rapamycin 
Telomerase is necessary to maintain telomere lengths in over 90% of 
cancers, imparting them with immortality [36]. To examine effects of perillyl 
alcohol or rapamycin on prostate tumor cell telomerase activity, we performed 
RTQ-TRAP on protein extracts obtained from perillyl alcohol- or rapamycin-
treated DU145 and PC3 cells. The drug treatment conditions used-400 pM 
perillyl alcohol for 16 hr or 10 nM rapamycin for 4 hr-were those shown 
previously to suppress 4E-BP1 phosphorylation in human prostate cancer cells 
and to inhibit cap-dependent translation via the mTOR pathway [144, 145]. 
Concentrations used also emulate plasma concentrations of the respective 
agents achieved in cancer patients [143, 159], For reference, EtOH- or DMSO-
treated control cell protein samples were also analyzed. RTQ-TRAP assay, used 
to assess telomerase activity, is preferred over previous TRAP methods due to 
its increased sensitivity and quantitative nature based on threshold cycle (CT) 













• « A 
• • * • a * •_» * 
In* 
10 

















DU145 DU145 DU145 PC3 PC3 PC3 
EtOH POH Rapa EtOH POH Rapa 
Treatment 
Fig. 7. Perillyl alcohol (POH) and rapamycin (Rapa) inhibit telomerase in 
DU145 and PC3 cells, (a) Relative levels of telomerase activity in prostate 
cancer cells with and without perillyl alcohol or rapamycin determined by RTQ-
TRAP. Cells were treated with one of the following: 400 pM POH for 16 hr, 10 
nM Rapa for 4 hr or 0.1% ethanol (EtOH) for 16 hr before lysis in CHAPS 
buffer. Open symbols: DU145 cells; solid symbols: PC3. *,0; EtOH. •,•: Rapa. 
A, A: POH. Representative results from DU145 and PC3 cell lines assessed by 
RTQ-TRAP. An increase in Cj value indicates a decrease in telomerase 
activity, (b) RTQ-TRAP assays were run in triplicate and the resultant CT 
values for each treatment condition and cell line were averaged. Remaining 
telomerase activity was determined as described in Methods relative to EtOH-
treated cells, which were set at 100%. Error bars shown represent the mean 
+/- standard deviation (SD) of three independent experiments; * represents 
significant differences as determined by ANOVA. 
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difference in starting material or in this case, a 50% reduction in telomerase 
activity; a CR value change of 3.3 represents a 10-fold difference or 90% 
reduction in activity. Fig. 7 (a) shows representative results from RTQ-TRAP 
experiments that were conducted on standardized protein concentrations at least 
three times. In the absence of reagents (EtOH only), DU145 cells (open circles) 
were found to have much greater telomerase activity than did PC3 cells (solid 
circles), i.e., the average CT value was lower for untreated DU145 for equivalent 
protein amounts than that found for untreated PC3 (24.7 and 27.4, respectively in 
the experiment depicted)-indicative of greater initial activity. Results from three 
separate experiments demonstrated that PC3 cells had ~17% of the telomerase 
activity found in DU145 cells. Disparate levels of telomerase activity have been 
noted previously for these two lines [183]. A large increase in Cj values (due to 
loss of telomerase activity) was identified in perillyl alcohol (open triangles)- and 
'4r 
8 
Fig. 8. Verification of telomerase activity in DU145 and PC3 cell extracts by 
PAGE. RTQ-TRAP generated amplicons were electrophoresed on a 10% non-
denaturing polyacrylamide mini-gel that was subsequently stained in SYBR 
Green and ethidium bromide. Lane 1: 100-bp markers included as a size 
reference. Lane 2: Rapamycin-treated PC3. Lane 3: Perillyl alcohol-treated PC3. 
Lane 4: PC3 EtOH-treated control sample. Lane 5: No template control sample. 
Lane 6: DU145 EtOH-treated control sample. Lane 7: Perillyl alcohol-treated 
DU145 sample. Lane 8: Rapamycin-treated DU145 cells. 
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rapamycin (open squares)-treated DU145 samples relative to controls (F= 
1214.996; df= 2; p<0.0005). Correspondingly, PC3 samples also showed 
attenuated telomerase upon perillyl alcohol (solid triangles) and rapamycin (solid 
squares) treatment compared to controls (F=40.275; df=2; p<0.0005). A 
Dunnett's test revealed the significant differences in both cell lines between 
perillyl alcohol and control treated sample (DU145 and PC3 p<0.0005), and 
between rapamycin and control treated samples (DU145 and PC3 p<0.0005). 
Resultant CT values for each treatment condition and cell line were averaged and 
remaining telomerase activity determined as described in Methods relative to 
EtOH-treated cells, which were set at 100% (Fig. 7, (b)). Perillyl alcohol and 
rapamycin inhibited telomerase activity in both cell lines. Treatment of PC3 
cells with perillyl alcohol resulted in ~80% loss of telomerase activity; a 70% 
reduction was observed with rapamycin. Correspondingly in DU145 cells, both 
perillyl alcohol and rapamycin dramatically attenuated telomerase activity (~93% 
and 98%, respectively). 
Telomerase activity results were confirmed by analyzing amplicons 
generated by RTQ-TRAP on non-denaturing 10% polyacrylamide gels as 
modified from Dikmen et al. [181] followed by SYBR Green/ethidium bromide 
staining (Fig. 8). The product from the no template control reaction was run on 
the gel to account for artifacts due to primer-dimer formation (Fig. 8, lane 5). 
RTQ-TRAP-generated amplicons produced a characteristic laddering pattern 
indicative of telomerase activity as seen in control lanes for PC3 and DU145 
cellular extracts (Fig. 8, Lanes 4 and 6 respectively). Greater telomerase activity 
(i.e. number of bands) and band intensities were again apparent in the control 
DU145 lane relative to PC3. In perillyl alcohol-treated samples for PC3 and 
DU145 cells, there was a marked decrease in the intensity of the ladder (lanes 3 
and 7, respectively), and an even further reduction in the intensity after 
rapamycin treatment (lanes 2 and 8 respectively), indicating decreased 
telomerase activity. Interestingly, we were able to detect the ladder using a mini-
gel. This enables electrophoretic gel analysis in 30 min, versus the standard gel 
run of 2-4 hrs. The waning intensity of the ladders confirmed that low 
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Tablet. 
Time course of perlltyl alcohol or rapamycln treatment effects on 
telomerase activity in DU145 cells.1 
Condition 1 hr 2 hr 4hr Bhr 16hr 
POH 82.8+/-19.9 86.5 +/-16.4 92.5 +/-12.8 
Rapamycin 88.2 *f- 4.5 922 +/- 5.4 98.3 *b 1.8 T T . I T  i  r  «  II II n r .  
'Percent reduction in telomerase activity relative to control untreated eels. Each 
value represents the mean of three independent replicates +/- standard deviation. 
POH » Perillyi Alcohol. Statistical significance of perilyi alcohol treatment vs. 
control or rapamytin treatment versus control was assessed using ANOVA with a 
Dunnetfs posthoc test. 
concentrations and short exposure times of perillyi alcohol or rapamycin were 
sufficient to decrease telomerase activity in DU145 and PC3 cells. 
The remarkable loss of telomerase activity after relatively brief incubations 
with either perillyi alcohol or rapamycin led to examination of even shorter 
treatment times to gain insights into their respective mechanisms of modulating 
telomerase. In addition, because DU145 cells had significantly greater amounts 
of telomerase activity compared to PC3, all additional studies focused on DU145. 
Cells were treated with rapamycin for 1 or 2 hr, or perillyi alcohol for 4 or 8 hr, 
after which they were lysed and assayed with RTQ-TRAP. Rapamycin markedly 
arrested telomerase activity by -88% +/- 4.5% (SD) within 1 hr (Table 1). 
Although much smaller and more simple structurally than rapamycin, perillyi 
alcohol likewise exerted substantial inhibitory effects at 4 hr and reduced 
telomerase by -83% +/-19.9% (SD); at 8 hr incubation, telomerase activity was 
attenuated by -87% +/- 16.4% (SD). The rapid inhibition of telomerase activity 
by perillyi alcohol and rapamycin provides insights for their mode of action. 
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Fig. 9. Quantitative real-time RT-PCR analysis of hTERT mRNA levels in DU145 
cells treated with perillyl alcohol or rapamycin. hTERT mRNA expression was 
determined based on CT values. Levels were normalized to the expression of 
HMG CoA reductase and expressed as fold change. No significant difference is 
detected when comparing treatment groups to control. Results are shown as a 
mean +/- SD of at least three experiments. 
Neither perillyl alcohol nor rapamycin alters hTERT mRNA levels 
Telomerase activity is regulated at both transcriptional and translational 
levels, although transciptional processes have been identified as the critcal 
governing factor [44], mRNA levels of hTERT, the rate limiting component of 
telomerase, correlate to telomerase activity [184]. Rapamycin-at high 
concentrations and/or for long periods (48 to 72 hr)-has been reported to 
decrease hTERT mRNA levels [146, 147]. Likewise, 24 hr cellular treatment with 
the isoflavone genistein reduced hTERT mRNA expression [185], Using real­
time RT-PCR, we examine if telomerase activity was altered by perillyl alcohol 
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Fig. 10. Western blot analysis to detect hTERT protein levels in DU145 cells 
following perillyl alcohol or rapamycin treatments, (a) Lanes 1-3 were loaded 
with 50 pg of DU145 total protein. Lane 1: control DMSO-treated sample. Lane 
2: 400 pM perillyl alcohol for 16 hr. Lane 3: 10 nM rapamycin for 4 hr. Lane 4: 
Precision Plus Protein™ WesternC™ Standards. Membrane in the top panel 
was probed with an anti-hTERT antibody, (b) Depiction of the western blot 
produced by probing with anti-elF4E antibody as a loading control. B. Histogram 
representation of four independent experiments +/-1 standard deviation. 
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rapamycin (Fig. 9). An internal control gene was included -HMG-CoA reductase-
whose mRNA level does not change in response to perillyl alcohol and 
rapamycin [145], Real-time RT-PCR analysis showed that at the 
pharmacologically relevant levels used during this study [143, 159], neither 
perillyl alcohol (0.4 mM, 16 hr) nor rapamycin (10 nM, 4 hr) produced a 
significant decrease in their respective average Ct values in DU145 cells as 
compared to untreated controls when normalized to HMG-CoA reductase levels 
as described in Livak and Schmittegn (F= 0.219; df=2; p= 0.808) [182], Thus, 
neither perillyl alcohol nor rapamycin-under the conditions used here-appear to 
regulate telomerase activity at the transcriptional level. 
hTERTprotein levels diminish after perillyl alcohol or rapamycin incubation 
Additional levels of telomerase regulation due to post-translational 
processes such as hTERT protein phosphorylation, cellular localization and/or 
degradation are known [43]. It was hypothesized that a direct translational effect 
due to suppressed 4E-BP1 phosphorylation and therefore decreased hTERT 
protein synthesis by either compound was likely. Further, due to the rapid rate of 
reduction observed in the above studies, telomerase activity inhibition may be 
additionally modulated at a post-translational level. Western blot analysis was 
then conducted to assess possible hTERT protein level changes in response to 
treatments with perillyl alcohol or rapamycin. After transfer onto PVDF, 
membranes were incubated with either rabbit anti-hTERT (detects ~122 kDa 
protein) or mouse anti-elF4E (~28 kDa protein) as a control for loading (Fig. 10 
(a)). Densitometric analysis was performed on the western blot bands; results 
from four independent experiments are shown (Fig. 10 (b)). Bands resulting from 
the DU145 protein lysates treated with either perillyl alcohol or rapamycin were 
compared to the band intensity resulting from the control-treated sample (lane 1, 
Fig. 10 (a)). Perillyl alcohol treatment reduced hTERT protein levels by ~30% 
(lane 2), whereas rapamycin treatment (lane 3) caused a -65% reduction in 
hTERT protein levels. Four independent experiments produced similar results 






Fig. 11. Western blot analysis to detect MKRN1 expression after perillyl 
alcohol or rapamycin treatment. Lanes 2-4 were loaded with 50 M9 of total 
protein from DU145 cells. Lane 1: Precision Plus Protein™ WesternC™ 
Standards. Lane 2: Rapamycin-treated sample. Lane 3: Perillyl alcohol -
treated sample. Lane 4: Control (DMSO)-untreated sample. Lane 5: HeLa 
nuclear extract (25 pg) was run as a positive control. Membranes were probed 
with anti-MKRN1 (top); antibody against elF4E was used as a loading control 
(bottom). 
of protein after rapamycin (F=63.893; df= 2; p<0.0005). A Dunnett's test further 
revelead that loss of hTERT protein caused by either perillyl alcohol or rapamycin 
were both highly significant (p<0.0005). Thus, perillyl alcohol and rapamycin 
lowered hTERT protein levels with short exposure times and at biologically 
relevant concentrations. This significant attenuation of hTERT protein by either 
agent supports an effect on protein translation mediated by the mTOR pathway. 
Degradation of hTERT by Makorin-1 does not appear to contribute to loss of 
hTERT protein 
Degradation of hTERT is controlled by Makorin-1 (MKRNI)-an E3 ligase 
that mediates ubiquitination of hTERT for proteasome processing [74, 75]. 
Cancer cells typically contain low MKRN1 levels [75], However, MKRN1 mRNA 
and protein levels rise dramatically in G1 arrest to signal the proteolytic 























Fig. 12. Western blot analysis to detect cellular localization changes after perillyl 
alcohol or rapamycin treatment, (a) Lanes 2, 4, and 6 were loaded with 40 pg of 
cytoplasmic protein from DU145 cells. Lanes 3, 5, and 7 were loaded with 40 pg 
of nuclear protein from DU145 cells. Lane 1: Precision Plus Protein™ 
WesternC™ Standards. Lanes 2 and 3: Control (EtOH)-untreated samples. 
Lanes 4 and 5: Perillyl alcohol-treated samples. Lanes 6 and 7: Rapamycin-
treated samples. Membranes were probed with anti-TERT antibody (Top); 
antibody against alpha-tubulin was used as a loading control (Bottom), (b) 
Histogram representation of four independent experiments +/- 1 standard 
deviation. 
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arrest in DU145 cells and a concomitant increase in p21ap levels [186]. Therefore 
western blotting was used to examine whether MKRN1 levels increased after 
either treatment, which would cause the ubiquitination and degradation of hTERT 
(Fig. 11). MKRN1 protein was not detected in control-treated DU145 cells (Fig. 
11, lane 4). Furthermore, no increase was noted with perillyl alcohol or 
rapamycin treatment (lanes 3 and 2, respectively). MKRN1 protein was 
observed in the control lane (lane 5) with 25 |jg nuclear extract from HeLa cells, 
which are reported to have low but measurable MKRN1 levels [75]. Longer 
exposures (20 min vs. 2 to 10 min) likewise did not reveal MKRN1 protein bands 
in DU145 cellular extracts. 
Cellular localization of hTERT and phosphorylation status 
Telomerase activity is also dependent on phosphorylation and nuclear 
localization of the hTERT protein [63]. Telomerase activity is thought to be 
modulated through phosphorylation of the hTERT subunit at Ser824 (and other 
sites such as Ser1125 and Ser227) by Akt protein kinase [61] and by various 
protein kinase C isoenzymes [67, 187, 188]. Conversely, decreased 
phosphorylation of Ser 824 with concomitant phosphorylation of Tyr707 is 
associated with hTERT export out of the nucleus into the cytoplasm [73, 189], 
To compare the effects of perillyl alcohol and rapamycin on hTERT cellular 
distribution, nuclear and cytoplasmic fractions were separated and hTERT levels 
in both fractions analyzed by western blotting (Fig. 12 (a)). hTERT protein was 
found in both the nucleus and cytoplasm of untreated DU145 cells, with greater 
protein in the cytoplasm. In response to isoprenoid or rapamycin treatment, no 
appreciable redistribution of hTERT protein from the nucleus into the cytoplasm 
was detected. Instead, protein levels in both fractions decreased relative to their 
counterpart control amounts. With the caveat that western blots are only semi­
quantitative, densitometric analyses of band intensities relative to alpha-tubulin 
(loading control) from four experiments revealed that in response to perillyl 
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Fig. 13. Western blot analysis to detect phosphorylation changes after perillyl 
alcohol or rapamycin treatment, (a) Lanes 2-4 and 7-9 were loaded with 50 pg 
of total protein from DU145 cells. Lanes 1 and 6: Precision Plus Protein™ 
WesternC™ Standards. Lanes 2 and 7: Control (EtOH)-untreated samples. 
Lanes 3 and 8: perillyl alcohol-treated samples. Lanes 4 and 9: Rapamycin-
treated samples. Lane 5 was loaded with running buffer. Membranes were 
probed with anti-phospho (Ser824)-TERT (Top left); anti-TERT (Top right); 
antibody against elF4E was used as a loading control (bottom), (b) Histogram 
analysis of five independent experiments +/-1 standard deviation. 
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cytoplasmic fraction decreased by -40 % (F=0.493; df=1; p=0.505) (Fig. 12 (b)). 
Rapamycin treatment mimicked this trend. hTERT protein in nuclear fractions 
declined by -77 % compared to that in the cytoplasm, which was reduced by -61 
% (F=0.151; df=1; p=0.709). In both situations, the respective reductions in 
nuclear and cytoplasmic hTERT protein levels were not significantly different 
than the total loss of protein observed after either treatment. The 
phosphorylation status of hTERT Ser824 in response to either treatment 
condition was also assessed (Fig. 13 (a) and (b)). The dephosphorylation 
pattern followed the reduction in hTERT protein levels. Results from four 
experiments showed that perillyl alcohol treatment caused a -41 % decrease in 
hTERT protein and a -56 % loss of hTERT (Ser824) phosphorylation (F=1.048; 
df=1; p=0,336) (Fig. 13 (b)). Rapamycin caused a -60 % reduction in hTERT 
protein and -46 % loss in Ser824 phosphorylation (F=2.315; df=1; p=0.167)(Fig. 
13 (b)). There is no significant difference in the the decrease in hTERT Ser824 
phosphorylation with either perillyl alcohol or rapamycin treatment versus the loss 
of hTERT protein observed. Hence the loss of telomerase activity is not due to a 
change in Ser824 phosphorylation or due to export of the protein from the 
nucleus. 
DISCUSSION 
The rate-limiting component of the telomerase holoenzyme, hTERT, is 
regulated by both transcriptional and post-transcriptional factors, such as mRNA 
levels, cellular localization of hTERT protein, hTERT phosphorylation and protein 
degradation [43], Somatic cells and normal cells in culture do not have 
detectable levels of hTERT mRNA, although the RNA component-/)TERC-is 
present [45]. Eventually normal cultured cells enter into crisis; all but a few will 
succumb to apoptotic death [46], The few cells that survive crisis become 
immortalized as detected by a surge in hTERT mRNA levels [45]. Comparable 
transcriptional derepression of hTERT is observed in patients' tumor cells relative 
to adjacent normal tissues [45]. The promoter region of the hTERT gene has 
multiple binding sites for a vast array of transcription factors, providing clues to 
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the extent of regulatory complexity [47]. Specifically, two Myc/Max binding sites 
(E-boxes) have been identified in the hTERT promoter, and c-myc directly 
activates hTERT transcription [48-50]. It is well known that c-myc activation is an 
early event in nearly all cancers as is telomerase activation. However, after 
hTERT transcription has been de-repressed, molecular failsafes remain to 
squelch the pro-cancer activities of a cancer cell apprentice. Posttranscriptional 
control of hTERT becomes the cell's last resort to forestall telomerase activation 
and therefore immortalization. 
Results of this study demonstrate that both perillyl alcohol and rapamycin 
attenuate telomerase activity without altering hTERT mRNA levels. The ability of 
perillyl alcohol-a structurally simple plant monoterpene-to inhibit telomerase 
activity has not been previously reported. These findings indicate that effects 
on hTERT core promoter by either perillyl alcohol or rapamycin are not involved 
in repression of telomerase activity. In addition, hTERT mRNA stability is an 
unlikely target because mRNA levels did not change within the time-frame 
studied. Thus perillyl alcohol and rapamycin appear to act as sentinels to 
counter increased hTERT mRNA levels. These results with perillyl alcohol 
contrast to those reported for genistein-a soybean-based natural product-and 
other isoflavones or plant products that appear to regulate telomerase 
transcriptionally [65, 161, 185, 190]. Likewise, epicatechins found in green tea 
have been reported to down-regulate hTERT mRNA levels in carcinoma cells 
[191]. Zhao (2008) and Zhou (2003) also found decreased hTERT mRNA levels 
with high concentrations (100 - 1000 nM) and long incubation times (48 to 72 hr) 
of rapamycin [146, 147], Others have established that genistein depletes 
telomerase via an epigenetic mechanism-through site specific hypo-methylation 
at an E2F-1 binding site in the hTERT promoter [60, 188]. 
In the absence of hTERT mRNA inhibition, we proposed that perillyl alcohol-
and rapamycin-mediated loss of telomerase activity were likely due to 
translational (hTERT protein synthesis) or a combination of translational and 
post-translational mechanisms such as phosphorylation, nuclear translocation or 
degradation of the hTERT protein. Our experiments clearly demonstrated that 
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both agents instigated a significant loss of hTERT protein. The half life of hTERT 
has been reported at ~ 6 to 12 hr depending on the cell type studied [178, 192]. 
Protein loss was observed at 4 hr treatments, therefore it could be due in part to 
inhibition of translation initiation and protein turnover attributed to effects of either 
compound on S6 kinase and/or 4E-BP1. Within this work, protein turnover 
cannot be ruled out or distinguished from degradation. Importantly the findings 
that rapamycin, the classical mTOR inhibitor, or perillyl alcohol, an isoprenoid 
with known anti-mTOR effects, both decrease hTERT protein provides 
compelling evidence that perillyl alcohol or rapamycin-mediated control of 
telomerase is due to translational mechanisms mediated by the mTOR pathway. 
Likewise our findings are noteworthy in that biologically relevant 
concentrations and brief exposure times for perillyl alcohol or rapamycin were 
used: 0.4 mM for 16 hr, and 10 nM for 4 hr, respectively. Under these conditions, 
suppressed phosphorylation of a downstream target of mTOR (4E-BP1), 
disruption of the m7GpppX cap binding complex elF2F and/or inhibition of cap-
dependent translation have been observed [144, 145, 193]. Shorter incubation 
times with either agent likewise resulted in attenuated telomerase activity. Thus 
the cellular effects are very rapid. In contrast, virtually all of the studies cited 
above-in which hTERT mRNA effects were observed-were performed for 24, 48, 
or 72 hrs. We believe the transcriptional effects on hTERT may be due to the 
secondary effects of shutting down cap-dependent translation through the mTOR 
pathway for a prolonged period of time. It should be emphasized that the 
maximum tolerated dose of oral rapamycin administered to adult cancer patients 
on a daily basis has been reported at ~6 mg/d, which results in a maximal 
plasma concentration of ~22 nM [143]. Correspondingly, the perillyl alcohol 
concentration used in this study emulates plasma concentrations of perillic acid-
the main metabolite of perillyl alcohol detected in patients [159, 194], The 
suprapharmacological rapamycin concentrations used in the above two in vitro 
studies and/or prolonged incubations are unwarranted, and effects observed 
likely reflect accumulating damage to cellular components, secondary metabolic 
effects and possibly autophagy [195]. In addition, drug studies conducted with 
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unrealistic concentrations may disguise the true cellular pathways modified or 
provide artifactual results [196, 197], 
Moreover, western blot results revealed that MKRN1- the E3 ligase known 
to target hTERT for degradation- was not up-regulated in perillyl alcohol- and 
rapamycin-treated cells, a result somewhat surprising based on several earlier 
reports linking hTERT degradation to MKRN1 [74, 75, 192]. However, the 
findings should have been anticipated to some extent. Although previous studies 
found that MKRN1 mRNA and protein levels rose dramatically (~6 fold) after 
either cell cycle arrest was induced [75] or a chaperone inhibitor geldanamycin 
was used [74], the enhanced MKRN1 protein levels occurred over a period of 6 
to 12 hrs [75]. Effects observed with both perillyl alcohol and rapamycin were 
much faster in the present experiments, in which diminished telomerase activity 
was measured 1 or 2 hr post-rapamycin incubation or after a 4 hr perillyl alcohol 
treatment. Due to the rapid decrease in protein observed in the current 
experiments, ubiquitination and proteasome breakdown of hTERT may indeed 
still have a role, but it is unlikely to involve MKRN1. Lee and Chung (2010) and 
Kim et al. (2005) have proposed that hTERT degradation may be mediated 
additionally by Hsp90/Hsp70-associated U-box ubiquitin ligase CHIP or other 
unidentified E3 ligases [74, 192], 
The rapidity at which a decline in telomerase activity was detected with 
rapamycin (1 hr) or with perillyl alcohol (4 hr) incubation led us to explore 
supplementary telomerase activity regulation at a post-translational level. 
Intracellular reshuffling of hTERT contributes to post-translational regulation of 
telomerase activity [63]. hTERT redistribution between the nucleus and 
cytoplasm with nuclear localization is thought to be essential for telomerase 
activity [63, 66]. However, our findings show that neither perillyl alcohol nor 
rapamycin causes cellular redistribution of hTERT. Interestingly, the average of 
the cytoplasmic and nuclear loss of hTERT is approximately equivalent to the 
total loss of hTERT seen in the previous studies (data not shown). 
As a corollary to the cellular localization studies, hTERT phosphorylation 
status was examined to confirm the absence of hTERT redistribution. 
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Phosphorylation events have been linked to hTERT exit from or entrance into the 
nucleus. In accordance with the above results, we did not detect a change in 
phosphorylation of hTERT (Ser824), which has been shown to be targeted by Akt 
[61]. Furthermore, our findings are consistent with previous observations that 
neither perillyl alcohol nor rapamycin suppressed Akt (Ser473) phosphorylation in 
prostate cancer cell lines [145]. Conversely, agents that do affect Akt kinase 
activity, such as a PI3-kinase inhibitor wortmannin, inhibit telomerase activity and 
downregulate hTERT protein phosphorylation [61]. Jagedeesh et al. (2006) also 
reported that 50 |jM genistein treatment of DU145 cells for three days decreased 
phosphorylation of Akt (Ser473) concomitant with a reduction of hTERT protein 
phosphorylation (non-specific serines) [65]. Likewise, hTERT translocation into 
the nucleus was prevented. Clearly a change in phosphorylation status did not 
contribute to the rapid loss of telomerase activity that we observed with our short, 
biologically relevant treatment parameters. 
Rapamycin has been touted as a new potent cancer chemopreventive agent 
[149, 150], but concerns about toxic side effects (immunosuppression), safety 
(feedback activation of Akt and enhanced tumorigenesis) and pharmacokinetic 
issues temper enthusiasm for this approach [151, 152], The potential efficacy of 
naturally occurring dietary factors with relatively low acute toxicity [153] contrasts 
to that of rapamycin; consequently, isoprenoids represent a more cogent and 
effective method for cancer prevention. Perillyl alcohol exhibits clear and 
definitive effects on a distinct signaling pathway-mTOR-that has a strong, critical 
clinical role as well as a role in cell proliferation. Dietary compounds such as 
isoprenoids likely contribute to chemoprevention by inhibiting a slight growth 
advantage (or hyperproliferation) in an early stage or pre-malignant cell, and 
there is evidence that metastasis and angiogenesis are also targeted [198]. In 
this study we have uncovered an additional target-telomerase activity-that may 
be paramount in the chemopreventive capacity of perillyl alcohol. All cancers are 
excellent candidates for chemopreventive measures and approaches, but 
prostate cancer is particularly appropriate due to its relatively long latency, late 
age of onset, slow growth, and high incidence [171, 199, 200]. Our findings also 
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emphasize that isoprenoids may be important clinically not as single agents but 
rather as chemotherapeutic adjuvants or sensitizing agents to diminish 
telomerase activity in tumor cells. 
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CHAPTER III 
DISRUPTION OF A HTERT-MTOR-RAPTOR PROTEIN COMPLEX BY THE 
PHYTOCHEMICAL PERILLYL ALCOHOL AND RAPAMYCIN 
INTRODUCTION 
Gene regulation is a complex process mediated by numerous cellular 
pathways. At the forefront of current gene regulatory mechanism research are 
post-translational modifications that alter the ability of a protein to perform its 
functions. Traditional mechanisms of post-translational regulation include protein 
folding, phosphorylation changes, and cellular localization. An equally important 
post-translational process is the assembly of proteins into complexes that allow a 
cell to carry out diverse functions that the individual proteins found in the complex 
could not perform on their own. Determining which proteins are in the complex of 
interest discloses clues about regulation of the cellular process imparted by the 
complex. This molecular puzzle of protein interactions in a complex ultimately 
reveals regulation. 
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that is 
the central player in numerous protein complexes. One of its primary functions, 
regulation of cap-dependent translation, is mediated through phosphorylation of 
4E-BP1. mTOR's association with various protein complexes imparts unique 
regulatory functions, a process that emphasizes the importance of protein-protein 
interactions and associated complex formation in expanding the regulatory role of 
individual proteins. For example, through multiple protein interactions mTOR not 
only regulates protein translation, but also cell growth and cell size, as well as 
autophagy and ribosome biogenesis. 
mTOR associates with RAPTOR in a complex termed mTORCI that 
governs cap-dependent translation [109]. Further, the downstream targets of 
mTORC1-S6K and 4E-binding protein 1 (4E-BP1 )-have been shown to 
physically associate with RAPTOR in a larger complex [201, 202]. mTORCI 
phosphorylates S6K and 4E-BP1, and complex formation apparently facilitates 
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the efficiency at which down-stream signaling may occur. Hsp90 likewise forms 
a physical complex with RAPTOR and is required for certain mTORCI functions 
in the complex [203, 204]. Furthermore, inhibition of Hsp90 decreases RAPTOR 
expression, suggesting that Hsp90 may stabilize this complex [204]. 
Hsp90 is also an integral part of the telomerase complex. Hsp90 and a co-
chaperone p23 are required for efficient telomerase activity [205]. Telomerase 
provides immortality to most cancer cells by extending telomeric DNA sequences 
with a hexameric repeat, thus allowing cancer cells to escape senescence. 
Human telomerase enzyme is minimally composed of hTERT-the catalytic 
subunit and reverse transcriptase-and hTERC, the RNA component [2, 16, 40, 
60]. Other proteins such as dyskerin have also been found to be supporting 
members in the telomerase complex. Kawauchi et al. further described that upon 
IL-2 stimulation of natural killer (NK) cells, telomerase activity was de-repressed, 
and hTERT protein formed a physical and functional complex with mTOR, S6K, 
Hsp90 and Akt [70], The inclusion of mTOR and S6K in the hTERT complex is 
persuasive evidence to support mTOR-mediated control of telomerase activity. 
Using a plant-derived isoprenoid-perillyl alcohol-and the classical mTOR 
inhibitor-rapamycin-we recently demonstrated that both agents rapidly and 
effectively attenuate telomerase activity and hTERT protein levels in human 
prostate cancer cells. These decreases in telomerase activity and hTERT 
protein levels occur in the absence of any effect on hTERT mRNA (Chapter 2). 
Both compounds were previously observed in our laboratory to suppress 4E-BP1 
phosphorylation and cap-dependent translation in cancer cells [144, 145], In 
addition, the known mechanism of action for rapamycin involves dissociation of 
the endogenous mTOR-RAPTOR complex with a concomitant suppression of 
mTOR kinase activity [139, 206]. The ability of perillyl alcohol to likewise disrupt 
the mTOR-RAPTOR complex as a mechanism to down-regulate protein 
synthesis has not been explored. 
Based upon the known important protein interactions described above, we 
hypothesized that an hTERT-mTOR-RAPTOR complex exists in prostate cancer 
cells. As demonstrated in this study, perillyl alcohol and rapamycin-mediated 
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dissociation of this complex has a unique role in post-translational inhibition of 
telomerase activity. 
MATERIALS AND METHODS 
Cell lines and cell culture 
Human prostate cancer cell line DU145 (American Type Culture Collection, 
Manassas, VA) was maintained at 37°C in a humidified incubator with 5% CO2 in 
RPMI-1640 medium supplemented with 10% fetal bovine serum, 1X glutamine 
and 1X penicillin/streptomycin. Growth medium was changed every other day. 
Drug treatments 
Perillyl alcohol (Sigma-Aldrich, St. Louis, MO) was prepared in 100% 
ethanol; rapamycin (Cell Signaling Technology, Danvers, MA) was dissolved in 
100% DMSO [145]. DU145 cells were plated at a concentration of 3x106 cells 
per 100 mm plate in 8 mL medium and allowed to attach overnight. Cells were 
then treated with one of the following: 400 pM perillyl alcohol for 16 hr, 10 nM 
rapamycin for 4 hr, or 0.1% ethanol for 16 hr as described by Peffley et al. [145]. 
Concentrations used emulate plasma concentrations of the respective agents 
reported in clinical studies on cancer patients [143, 159], 
Protein extraction and immunoprecipitation 
Cells were extracted using the Pierce® Classic IP kit according to the 
manufacturer's instructions. The IP lysis/wash buffer was supplemented with 1X 
Complete protease inhibitor cocktail (Roche Applied Science), 1 mM Na3V04 and 
1 mM NaF. Protein concentration was interpolated using a Bradford assay and 
extracts were either analyzed immediately or stored at -86°C. 
The complex of interest was captured using the Pierce® Classic IP kit 
according to the manufacturer's instructions. Briefly, 5 pg of rabbit polyclonal 
anti-RAPTOR antibody (Millipore) or 5 pg of anti-IgG (clone Sc-2027; Santa 
Cruz) was incubated overnight with 1 mg of protein extract in the IP lysis/wash 
buffer with end-over-end mixing. Protein A-Sepharose from Staphylococcus 
aureus (Sigma-Aldrich®) was resuspended (1:1) in PBS. Thirty |JL of protein A-
Sepharose slurry was applied to the Pierce spin column. Washes were carried 
out according to the manufacturer's protocol. The protein-antibody solution was 
applied to the spin column containing protein A-Sepharose and incubated for 1 hr 
at 4°C with end-over-end mixing. Subsequent washes were carried out 
according to the manufacturer's protocol. The complex was eluted from the 
column/beads following the sample-buffer elution protocol provided in a 2X SDS 
loading dye. Eluted protein was subsequently used in the western blot protocol. 
SDS-PAGE and western blot 
One half the volume of captured protein was loaded per well on a 4-15% 
polyacrylamide TGX mini-gel (Bio-Rad) and resolved by electrophoresis in 1X 
Tris-glycine-SDS (0.025 M Tris, 0.192 M glycine, 0.1% SDS, pH 8.3) for 30 min 
at 200 volts. Odyssey® two-color protein molecular weight markers were 
included to determine protein sizes; all subsequent steps were performed with 
minimal light exposure. Electrophoretic transfer onto polyvinylidene fluoride 
(PVDF) membrane was performed in 1X Tris-glycine buffer. Membranes were 
blocked in protein-free blok-CH™ buffer (Millipore) for 1 hr at room temperature 
and then incubated with gentle rocking in one of the following primary antibodies: 
rabbit polyclonal anti-RAPTOR (1:1,000; Millipore) (capture/loading control), 
rabbit polyclonal anti-hTERT (1:1000; clone Y182, Millipore), rabbit polyclonal 
anti-mTOR (1:1,000; Cell Signaling Technology®), rabbit polyclonal anti-Hsp90 
(1:1,000; clone C45G5, Cell Signaling Technology®), or rabbit polyclonal anti-
p70 S6 kinase (1:1000; Cell Signaling Technology®). 
Incubations were conducted overnight at 4°C and followed by extensive 
washes in 1X Tris-buffered saline (TBS)-Tween 20 (0.02M Tris, pH 7.4, 0.15 M 
NaCI, 0.05% Tween 20). IR-conjugated secondary antibodies (goat anti-rabbit 
[IRDye 680LT] or goat anti-mouse [IRDye 800 C\N]) were diluted 1:5000 in blok-
CH™ buffer and incubated for 1 hr at room temperature. Subsequent membrane 
washes were as described [145], and then blots were washed for 5 min in PBS 
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before capturing images on an Odyssey Infrared Imaging System (Licor®). Band 
intensities were assessed subjectively. 
SDS-polyacrylamide gel silver staining 
Immunocaptured proteins separated by SDS-polyacrylamide gel 
electrophoresis were detected by silver staining using the Pierce® Silver Stain Kit 
according to the manufacturer's suggestions. Experiment was repeated twice 
with similar results. 
RESULTS 
Perillyl alcohol or rapamycin treatment causes changes in the protein complex 
associated with RAPTOR 
We previously demonstrated in DU145 prostate cancer cells that perillyl 
alcohol and rapamycin dramatically and rapidly attenuate telomerase activity 
without altering hTERT mRNA levels (Chapter 2). With these two agents, 
suppressed phosphorylation of a downstream target of mTOR (4E-BP1), 
disruption of the m7GpppX cap binding complex elF2F and/or inhibition of cap-
dependent translation have been observed in our laboratory [144, 145]. 
Importantly, hTERT protein levels were diminished by both agents, supporting an 
effect on 4E-BP1 and/or S6K phosphorylation and reduced initiation of protein 
translation. However, we also noted that the reduction in hTERT protein did not 
coincide wholly with loss of telomerase enzymatic activity, suggesting a further 
level of regulation. Rapamycin in complex with FKBP12 (FK506- binding protein 
of 12 kDa) causes the dissociation of RAPTOR from mTOR, disrupts coupling of 
mTOR with its substrates and interferes with its kinase ability [206]. We 
therefore reasoned that the rapid modulation of telomerase activity in DU145 
cells by perillyl alcohol or rapamycin was attributable in part to destabilization of 
an hTERT-mTOR-RAPTOR complex. 
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Fig. 14. Perillyl alcohol and rapamycin induce changes in proteins 
immunoprecipitated with RAPTOR in DU145 prostate cancer cells. Cells were 
treated with 400 |JM perillyl alcohol (POH) for 16 hr, rapamycin (Rapa) at 10 
nM for 4 hr, or 0.1% ethanol (EtOH) for 16 hr. Cellular extracts (500 pg) were 
incubated with anti-RAPTOR or anti-IgG antibodies and captured on Protein 
A-Sepharose. Proteins were eluted from the column/beads, separated by 
SDS-PAGE and detected by silver staining. Lane 1: Odyssey® two-color 
protein molecular weight markers (M). Lanes 2-5: 25 (il of eluted protein from 
the column/beads treated as indicated. Lettered arrows point out bands of 
interest. 
Thus we used co-immunoprecipitation with a RAPTOR antibody and 
protein gel silver staining to detect RAPTOR-associated proteins in DU145 cells 
and to elucidate potential changes to the captured protein complex caused by 
either 400 pM perillyl alcohol for 16 hr, or rapamycin at 10 nM for 4 hr. 
Treatment with either perillyl alcohol or rapamycin modified the protein complex 
captured with RAPTOR antibody compared to untreated cells; moreover distinct 
differences were found between the two agents (Fig. 14). The pronounced 
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Fig. 15. Perillyl alcohol and rapamycin destabilize the hTERT-mTOR-
RAPTOR complex found in DU145 prostate cancer cells. Representative 
western blots of RAPTOR-immunoprecipitated proteins are shown. Cells 
were treated and immunoprecipitated as described in Figure 14. After 
capture with anti-RAPTOR antibody and separation on SDS-PAGE, proteins 
were transferred to a PVDF membrane, and blocked prior to incubation with 
primary antibodies, (a) Blots were subsequently probed with anti-RAPTOR, 
anti-Hsp90, anti-S6K, or anti-mTOR antibodies as indicated, (b) Blots were 
probed with anti-RAPTOR or anti-hTERT antibodies. IgG: Negative control 
anti-IgG captured protein from EtOH-treated DU145 cells. All experiments 
were replicated at least five times with similar results. 
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respectively. Perillyl alcohol and rapamycin both suppressed proteins of 
approximately 170-180 kDa (A) and ~75 kDa (C) molecular mass (Fig. 14). The 
decrease in the 75 kDa (C) protein appeared to be greater with rapamycin than 
with perillyl alcohol (Fig. 14). Interestingly, rapamycin caused the loss of a -100 
kDa (B) protein, whereas perillyl alcohol increased the level of a protein at the 
same position on the gel (Fig. 14). Most noteworthy was the addition of a ~60 
kDa (D) protein to the complex by both perillyl alcohol and rapamycin treatments 
(Fig. 14). 
Perillyl alcohol or rapamycin causes hTERT, S6K, Hsp90, and mTOR to 
dissociate from RAPTOR 
Cellular functions are often revealed through identification of protein 
complexes. Therefore, we assessed by western blotting for the presence or 
absence of protein partners described originally by Kawauchi et al. in an 
immunoprecipitated complex [70], In control EtOH-treated cell extracts, 
immunoprecipitation with RAPTOR captured mTOR, S6K, Hsp90, and hTERT 
(Fig. 15 (a) and (b)) affirming the presence of a similar complex in DU145 cells. 
The above proteins were not detected when cellular extracts were 
immunoprecipitated with normal rabbit IgG. Although binding of 4E-BP1, a 
known RAPTOR-interacting protein, to the complex is of interest, it has a 
molecular weight of ~15-20 kDa; therefore its presence is masked by the IgG 
light chain. Further, the interaction between RAPTOR and 4E-BP1 has been 
previously confirmed [201, 207], 
Similarly, Akt, has a molecular weight of 60 kDa, consequently the heavy 
chain IgG band conceals the protein band. However, immunoprecipitation with 
anti-Akt antibodies revealed the presence of hTERT, Hsp90, and mTOR (data 
not shown). The Hsp90 band was the most intense confirming a direct physical 
interaction with Akt. Additionally, the amount of these proteins that 
immunoprecipitated with Akt decreased in response to perillyl alcohol or 
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Fig. 16. Anti-mTOR immunoprecipitation confirms perillyl alcohol or 
rapamycin-mediated disruption of the hTERT-mTOR-RAPTOR complex. Cells 
were treated as described in Figure 14. Immunoprecipitations were conducted 
with either anti-mTOR or anti-IgG antibodies as a control. Blots were 
subsequently probed with anti-mTOR, anti-hTERT, anti-RAPTOR, anti-Hsp90 
or anti-S6K antibodies as indicated. IgG: Negative control anti-IgG captured 
protein from EtOH-treated DU145 cells. POH, perillyl alcohol. All experiments 
were replicated at least five times with similar results. 
they are not physically interacting with one another, but rather they are in the 
complex through common associations with another protein (data not shown). 
Upon treatment with either perillyl alcohol or rapamycin, S6K completely 
dissociated from RAPTOR (Fig. 15 (a)). Additionally, a reduction in the amount 
of Hsp90 bound to RAPTOR was observed after either treatment. As expected 
based on previous literature reports, mTOR also separated from RAPTOR in 
cells treated with rapamycin [139]. A decrease in mTOR binding to RAPTOR 
mTORCl 
Fig. 17. Amended schematic model of the hTERT-mTOR-RAPTOR 
complex in DU145 cells. This schematic represents a more accurate 
model of the protein-protein interactions involved in the hTERT-mTOR-
RAPTOR complex based upon our immunoprecipitation results. 
Treatment with either perillyl alcohol or rapamycin impairs the structural 
integrity of the complex. 
was similarly noted in perillyl alcohol-treated samples, although the reduction 
was not as great as that detected with rapamycin (Fig. 15 (a)). Most interesting 
for our studies was the loss of hTERT binding to the RAPTOR-captured complex 
after treatment with either agent (Fig. 15 (b)). Importantly, perillyl alcohol caused 
a larger loss of hTERT protein than rapamycin did. This finding coupled with our 
previous reported results on the ability of these agents to attenuate telomerase 
activity and protein levels further supports our hypothesis of mTOR-mediated 
translational and post-translational regulation of hTERT. 
Perillyl alcohol or rapamycin causes hTERT, S6K, Hsp90, and RAPTOR to 
dissociate from mTOR 
As a corollary experiment, an antibody directed against mTOR was also 
used to co-immunoprecipitate the hTERT-mTOR-RAPTOR complex. The ability 
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of perillyl alcohol or rapamycin to compromise the structural integrity of the 
complex was also examined. Capturing protein binding partners in the complex 
with a different antibody could also potentially reveal specific physical 
interactions. Western blot analysis demonstrated that the mTOR antibody 
immunoprecipitated RAPTOR, Hsp90, S6K and hTERT (Fig. 16). Similarly, 
interactions among all four proteins with mTOR were disrupted by perillyl alcohol 
and rapamycin. Rapamycin and perillyl alcohol treatment decreased binding of 
RAPTOR and Hsp90 to mTOR, with rapamycin being more effective than perillyl 
alcohol. Although we detected a decrease in the hTERT and S6K bands upon 
treatment with either agent, the basal protein levels that immunopreciptated with 
mTOR were low. Our results are consistent with the postulate that the interaction 
between these two proteins with mTOR is via RAPTOR. 
DISCUSSION 
Protein complexes are the capstone of numerous cellular processes. 
Protein-protein interactions within these complexes add unique functions that 
individual proteins lack. Although it was surprising to find hTERT associated with 
a protein complex that included mTOR, it does provide a critical link between 
telomerase activity and a major signal transduction pathway that regulates cell 
cycle progression [70], Here we have found that a complex similar to that 
described by Kawauchi et al. in NK cells also exists in DU145 prostate cancer 
cells [70]. To the best of our knowledge, this is the first report of an hTERT-
mTOR-RAPTOR complex in cancer cells implicating the involvement of mTOR in 
controlling telomerase activity. 
We previously demonstrated that perillyl alcohol or rapamycin individually 
inhibited telomerase activity and decreased hTERT protein levels (Chapter 2). 
We did, however, note discordance between the almost complete abrogation of 
telomerase activity and the moderate decrease in protein levels. Under our 
standard treatment conditions, both compounds down-regulated telomerase 
activity by greater than 90% (Chapter 2). Our previous results also noted that 
rapamycin decreased hTERT protein levels more effectively than did perillyl 
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alcohol: a 76% reduction versus a 40% loss, respectively. Such findings led us 
to explore alternative post-translational regulation, i.e., the destabilization of a 
multi-protein complex. 
In the current study we demonstrate that treatment with either perillyl 
alcohol or rapamycin at short incubation times and biologically relevant 
concentrations disrupts this complex. Perillyl alcohol was as effective as 
rapamycin at dislodging hTERT from the hTERT-mTOR-RAPTOR complex. The 
smaller structure and lipophilic nature of perillyl alcohol might facilitate its 
diffusion into the complex and cause disruption of critical hydrophobic 
interactions. Based on our results, we propose that the ability of perillyl alcohol 
or rapamycin to perturb the functional hTERT-mTOR-RAPTOR complex helps 
resolve the variance noted between telomerase activity and hTERT protein loss 
in our previous study (Chapter 2). 
Surprisingly, both losses and gains in RAPTOR-associated proteins were 
detected by silver stained gel analysis after perillyl alcohol or rapamycin 
treatment. We anticipated that either agent would destabilize the complex; 
therefore decreases in ~160 kDa (A) and 75 kDa (C) proteins after treatment 
supported our hypothesis (Fig. 14). However, analysis of the silver-stained gel 
also revealed the addition of a ~60 kDa (D) protein after treatment with either 
agent (Fig. 14). Further, perillyl alcohol caused the association of ~100 kDa (B) 
protein (Fig. 14). Although future studies are needed to identify these proteins by 
mass spectrometry, we believe the proteins are likely telomerase inhibitors that 
associate with RAPTOR post-treatment. 
Others have reported drug-mediated disruption of protein-protein 
interactions between proteins in the hTERT-mTOR-RAPTOR complex; however 
we are the first to indicate complete dissociation of the multi-protein complex by 
either a simple phytochemical-perillyl alcohol-or rapamycin. In separate studies, 
rapamycin and curcumin were found to interrupt the mTOR-RAPTOR interaction 
[139, 208], Geldanamycin-a Hsp90 inhibitor-not only displaced Hsp90 from 
RAPTOR [204], but additionally dislodged hTERT from Hsp90 leading to hTERT 
degradation [74], Rapamycin and geldanamycin are both polyketide macrocyclic 
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antibiotics from S. hygroscopicus known to compromise protein-protein 
interactions [209]. Importantly, rapamycin inhibits Hsp90 complexes through 
modulation of the immunophilins FKBP52/54 [209]. These immunophilins are in 
the same family as the binding partner of rapamycin, FKBP12. The rapamycin-
FKBP12 complex dissociates mTOR from RAPTOR by binding a hydrophobic 
pocket on the mTOR surface [206, 210], Perillyl alcohol-a lipophilic compound-
likely utilizes a similar mechanism to destabilize the hTERT-mTOR-RAPTOR 
complex. 
Based on the RAPTOR and mTOR co-immunoprecipitation results reported 
in this study, as well as previous reports of known protein interactions, we 
developed a schematic representation of the hTERT-mTOR-RAPTOR complex 
(Fig. 17) [70, 139, 201-205, 211]. In the diagram, RAPTOR nucleates a complex 
among 4E-BP1, S6K, mTOR, hTERT, Akt, and Hsp90. Although Yip et al. report 
mTORCI as an obligate dimer necessary for mTOR enzymatic activity, we have 
represented the hTERT-mTOR-RAPTOR complex as monomeric for clarity [109, 
206]. RAPTOR serves as the scaffold that allows mTOR to phosphorylate its 
downstream targets-S6K and 4E-BP1-by physically binding them through a TOS 
motif [207], thus bringing them in close proximity to mTOR [201, 202, 204], Other 
studies report that Hsp90 forms a physical complex with RAPTOR and is 
necessary for the mTORCI functions of the complex, serving as another 
stabilizing scaffold [203, 204], Additionally, Akt, an upstream effector of mTOR, 
was found in a physical complex with mTOR, supporting the idea that kinases 
must physically interact with their substrates [212]. Similarly, Akt phosphorylates 
TERT, and therefore, their presence together in the complex is not surprising 
[61]. TERT requires interaction with both Hsp90 and Akt-which also interact with 
each other-for efficient telomerase activity [70, 211, 213]. Hsp90 promotes and 
maintains large protein complexes, such as the proposed hTERT-mTOR-
RAPTOR complex [214]. Thus placement of each protein within the diagram was 
based upon our results and previous reports of protein-protein interactions (Fig. 
17) [70, 139, 201-205, 211]. As discussed earlier, rapamycin-and by inference 
perillyl alcohol-destabilizes both of the scaffolds-Hsp90 and RAPTOR- present 
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in the complex. Within this context, our results clearly show that rapamycin and 
perillyl alcohol cause dissociation of the hTERT-mTOR-RAPTOR complex, 
possibly providing a mechanism of action by which these agents decrease 
telomerase activity in prostate cancer cells. 
In addition to enabling protein kinase activities, we venture that this large 
multiprotein complex has still more purposes. We further hypothesize that the 
physical interaction between mTOR and TERT is necessary for cancer cell 
survival [215], By usurping the mTOR pathway, the cell may evade two 
impediments to long term survival. Constitutively active mTOR in the hTERT-
mTOR-RAPTOR complex may stimulate TERT to ensure cancer cell immortality. 
An alternative potential role for the hTERT-mTOR-RAPTOR complex is to enable 
additional hTERT cellular functions, primarily DNA repair [84, 85]. Evidence 
supporting this premise is the discovery by Yip et al. that the dimeric mTORCI 
complex has a central cavity large enough to accommodate double-stranded 
DNA [206]. Furthermore, mTOR is a member of the PIKK family, several of 
which mediate DNA repair [216]. 
Understanding the elaborate interplay among proteins that form this 
complex has established further regulation of the telomerase enzyme by the 
mTOR pathway. Agents that disrupt protein-protein interactions represent a 
novel class of telomerase inhibitors and potential therapeutics [217], We 
propose that perillyl alcohol and rapamycin inhibit telomerase activity through 
unique synergistic decreases of hTERT protein translation and disruption of the 
hTERT-mTOR-RAPTOR protein complex. These findings strengthen the 
argument for use of perillyl alcohol as a potent cancer chemopreventive. 
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CHAPTER IV 
EIF4E OVER-EXPRESSION IMPARTS PERILLYL ALCOHOL AND 
RAPAMYCIN-MEDIATED REGULATION OF TERT 
INTRODUCTION 
Gene expression is tightly regulated by both transcriptional and translational 
processes. Although transcriptional control has long been touted as the principle 
regulator of gene expression, it is now clear that cells depend on translational 
regulation for rapid changes in protein levels. In eukaryotes, translational gene 
control is mediated mainly at the rate-limiting step of initiation [218]. Translation 
initiation is governed by a protein complex known collectively as elF4F 
(eukaryotic initiation factor 4F) that includes elF4A-a known RNA helicase, 
elF4G-a scaffold protein, and elF4E-the rate-limiting cap-binding protein [219], 
Together, the proteins that comprise elF4F ensure that secondary structure in 
the 5'-UTR (untranslated region) of mRNA is unwound to allow initiation of 
protein translation [112]. 
Not all mRNA sequences are able to compete equally for available elF4E. 
mRNAs with 5'-UTRs that are G-C rich have substantial secondary structure that 
attenuates initiation of translation. Consequently, greater elF4E levels are 
required to form the cap-binding complex, elF4F, which unfolds secondary 
structure and permits efficient cap-dependent translation. mRNAs with extensive 
secondary structure are generally not translated in the presence of low cellular 
elF4E levels, but instead are activated with mitogens through the mTOR pathway 
[115-117], Additionally, elevated elF4E levels associated with tumorigenesis 
have been shown to increase the translation of many oncogenic proteins. Free 
elF4E levels are therefore tightly regulated through mitogenic activation of the 
mTOR signal transduction pathway [118]. 
Regulation of the rate of cap-dependent translation is mediated through the 
PI3K/Akt/mTOR pathway [99]. Under quiescent conditions, elF4E is sequestered 
by 4E-BP1 in a configuration that prevents elF4E from partaking in translation 
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initiation. Upon growth factor stimulation, a kinase cascade is activated that 
results in mTOR phosphorylating 4E-BP1, which causes elF4E to dissociate 
[220]. Conversely, when cells encounter stressors that inhibit mTOR signaling, 
this cellular pathway ensures that proteins typically synthesized by cap-
dependent translation are not generated. Not unlike many important pathways in 
the cell, mTOR signaling and therefore cap-dependent translation is frequently 
aberrant in cancer cells and is a leading target for anti-cancer therapies [218]. 
Treatment of cancer cells with the canonical mTOR inhibitor-rapamycin-causes 
decreased 4E-BP1 phosphorylation, therefore reducing the level of free elF4E for 
translation initiation [142]. Additionally, our laboratory found that plant-derived 
compounds such as perillyl alcohol or genistein affect protein translation in 
cultured prostate cancer cells by modulating mTOR signaling [145], specifically 
both compounds decrease 4E-BP1 phosphorylation. Perillyl alcohol also disrupts 
the elF4F 5'- cap-binding complex by suppressing interaction of elF4E with 
elF4G. 
elF4E is overexpressed in almost all cancers including carcinomas of the 
prostate, breast, lung, bladder, cervical, and head and neck [118]. elF4E 
overexpression not only leads to many of the phenotypic changes associated 
with cancer cells including rapid proliferation, decreased apoptosis, and 
malignant transformation, it is also associated with a poor prognosis in human 
cancer patients [118, 221], Most cancer cells are also characterized by a de­
repression of telomerase, a ribonucleoprotein responsible for elongating 
telomeres by the addition of hexameric repeats that cause cellular 
immortalization [36], Similar to elF4E, hTERT, the rate limiting enzymatic portion 
of telomerase, is re-activated as an early and critical event in tumor cells. 
Importantly, we previously observed that perillyl alcohol or rapamycin 
treatment of prostate cancer cells was associated with a significant and rapid 
loss of telomerase activity concomitant with a decrease in hTERT protein levels 
(Chapter 2). This finding strongly suggests that TERT protein levels and 
telomerase activity are mediated in part by the mTOR pathway, the master 
regulator of elF4E. The above telomerase-mTOR regulatory phenomenon was 
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observed in tumor cells that endogenously over-express elF4E. Here we 
examined the mTOR contribution to telomerase activity in an immortalized non-
tumorigenic mammalian cell line with forced expression of elF4E. The distinction 
between a cancer cell with elevated elF4E and a normal immortalized cell with 
forced elF4E expression will allow us to tease apart the elF4E effects on 
telomerase activity versus those that may be mediated by other oncogenic 
pathways. 
MATERIALS AND METHODS 
Cell Lines and Cell Culture 
Chinese hamster ovary (CHO)-derived cell lines (rb4E and pMV7) were 
maintained at 37°C in a humidified incubator with 5% C02 in MEM medium 
supplemented with 10% fetal bovine serum, 1X glutamine and 1X 
penicillin/streptomycin. Growth medium was changed weekly. 
Geneticin Selection 
CHO cells permanently transfected with the vector pMV7-elF4E containing 
the cDNA sequence for murine elF4E under the regulation of a thymidine kinase 
promoter and a neomycin (neo) resistance gene or transfected with an empty 
vector (pMV7-neo) were created previously by Buechler and Peffley [144] and 
designated rb4E and pMV7, respectively. Vectors were originally provided by 
Nahum Sonenberg. Prior to initiating experiments, both cell lines were selected in 
geneticin (G-418) (Gibco/lnvitrogen, Carlsbad, CA) according to manufacturer's 
suggestions to verify the presence of vectors. Briefly, a stock solution of 
geneticin was made by dissolving it in PBS at a concentration of 50 mg/mL and 
then sterile filtering. pMV7, rb4E, and control non-transfected cells were plated 
at 1 X 106 in a 25 cm2 flask with 10 mL of MEM media supplemented with 10% 
FBS. After an overnight incubation, geneticin was added to a final concentration 
of 0.4 mg/mL. Media was replaced at least weekly and supplemented with 
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geneticin for an additional 3 weeks to ensure only transfected cells would 
survive. 
Drug treatments 
Perillyl alcohol (96% stock, Sigma-Aldrich, St. Louis, MO) was prepared in 
100% ethanol; rapamycin (stock 100 pM, Cell Signaling Technology, Danvers, 
MA) was dissolved in 100% DMSO [145]. pMV7 and rb4E cells were plated at a 
concentration of 5x10s cells per 60 mm plate in 3 mL medium and allowed to 
attach overnight. Cells were then treated with one of the following: 400 pM 
perillyl alcohol for 16 hr, 10 nM rapamycin for 4 hr, or 0.1% ethanol for 16 hr as 
described by Peffley et al. [145], Concentrations used of either compound are 
those that can be achieved in cancer patient plasma [143, 159]. 
Protein Extraction for Telomerase Activity 
Cells were plated at a concentration of 1x106 cells per 60 mm plate in 3 mL 
medium. Cells were harvested using trypsin-EDTA (ethylenediaminetetraacetic 
acid) and then pelleted by centrifugation (500 x g) for 8 min. Cell pellets were 
washed with ice cold phosphate-buffered saline (PBS) and subsequently 
centrifuged again. Protein lysates were obtained by resuspending pMV7 or rb4E 
cells in 200 pL of ice cold 1X CHAPS lysis buffer per 1 x 106 cells. The CHAPS 
lysis method was modified from that presented in Hou et al. and others [176-
179], CHAPS lysis buffer consisted of 0.5% 3-[(3-
Cholamidopropyl)dimethylammonio]-l-propanesulfonic acid (CHAPS), 10 mM 
Tris-HCI, pH 7.5, 1 mM MgCI2, 1 mM ethylene glycol tetraacetic acid (EGTA), 
and 10% glycerol. RNase inhibitor (New England Biolabs, Beverly, MA) (final 
concentration of 10 units/mL) and R-mercaptoethanol (BME) (Sigma-Aldrich, final 
concentration of 5 mM) were added just prior to use. Cell lysates were incubated 
at 4°C for 30 min and then centrifuged at 12000 x g for 30 min at 4°C. The 
supernatant was collected, protein concentration was interpolated using a 
Bradford assay and extracts were stored at -86°C. 
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RTQ-TRAP Assay 
Telomerase activity was detected by performing RTQ-TRAP as derived from 
a protocol described by Hou et al. [178], In detail, each 25 |JL RTQ-TRAP 
reaction contained: 1X SYBR Green Master mix (50 mM KCI, 20 mM Tris-HCI, 
pH 8.4, 0.2 mM each dNTP, 3 mM MgCI2, iTaq DNA polymerase at 0.05 units/pL) 
(Bio-Rad, Richmond, CA), 10 mM EGTA, 0.2 pg T4 gene protein (New England 
Biolabs), 0.35 \iM TS primer (5-AATCCGTCGAGCAGAGTT-3') (Tm 53.6°C) and 
0.35 pM ACX primer [5'-GCGCGG(CTTACC)3 CTAACC-3] (Tm 66.4°C) [180], 
and 2.5 pg of protein extract. Primers were purchased from Integrated DNA 
Technology (IDT, Coralville, IA). All samples were analyzed in duplicate in a 96-
well plate on a Bio-Rad CFX96 thermal cycler, and 1X CHAPS buffer was 
included as a negative control. Reactions were incubated at 25°C for 20 min to 
allow for elongation of the TS primer by cellular telomerase. The PCR protocol 
began with a 95°C hot start to activate Taq polymerase, followed by 40 cycles at 
95°C for 20 s, 50°C for 30 s, 72°C for 90 s [178], ending with a melt curve 
protocol. Telomerase activity was comparatively assessed based on threshold 
cycles (CT) [178], CT values greater than 35 were considered false positives due 
to primer dimers. Experiments were conducted at least three times. Inhibition of 
telomerase activity was determined as follows: 
(CT treatment) - (CT control) = ACJ 
(1 / 24CT) X 100 = % ACTIVITY REMAINING 
RNA extraction and quantification 
Total cellular RNA was isolated using PureZOL™ (Bio-Rad) according to the 
manufacturer's protocol. RNase-free-DNase I digestion (50 units) (Roche 
Applied Science, Indianapolis, IN) was also performed. RNA quantification was 
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determined by UV absorbance on a BioPhotometer Plus (Eppendorf®, Hamburg, 
Germany). 
TERT mRNA Levels 
Expression of TERT mRNA was detected using real-time RT-PCR. One pg 
of purified cellular RNA from untreated and treated cells was reverse transcribed 
into cDNA using iScript (Bio-Rad) at 42°C for 30 min in the presence of random 
hexamers and oligo(dT), Moloney murine leukemia virus reverse transcriptase 
and RNasin. Additionally, minus reverse transcriptase and a minus RNA 
template reactions were included as negative controls. Analysis of TERT mRNA 
expression was performed by real-time PCR amplification using a Bio-Rad 
CFX96 thermal cycler. The complete Chinese hamster (Cricetulus griseus) 
TERT sequence is not defined, therefore the Chinese hamster shotgun sequence 
(AFTD01128649.1) was aligned with the known Golden hamster (Mesocricetus 
auratus) telomerase catalytic subunit (accession number AF149012). PCR 
primer sets for Chinese hamster TERT and an internal control gene p-actin 
sequence (Cricetulus griseus beta actin [ACTB], accession number U20114) 
were optimized using Beacon Designer software (PREMIER Biosoft International, 
Palo Alto, CA). PCR efficiencies for each primer set were determined in triplicate 
by a dilution series of the cDNA template. A master mix contained 1X SsoFast 
EvaGreen (Bio-Rad), 0.5 pM of each forward and reverse primer, and 1.5 pi of 
cDNA per reaction. 
A 129-bp hamster TERT amplicon was generated using 5'-
AGCATCATCTCCAACATAGC-3' (Tm 52.3°C) and 5'-TCGGTAGCAGACCAAC-
3' (Tm 52.2°C). A 185-bp hamster p-actin gene amplicon was generated using 
5'-GCACCACACCTT CT ACAAC-3' (Tm 52.9°C) and 5'-
TACGACCAGAGGCATACAG-3' (Tm 52.7°C). The real-time PCR program used 
was 95°C for 30 s, followed by 35 cycles at 98°C for 30 s, 65°C for 30 s, ending 
with a melt curve analysis step where the temperature was reduced to 65°C, then 
increased to 95°C in 0.2°C increments every 5 s. The AACT method was used to 
comparatively analyze the data as described in Livak and Schmittgen [182]. 
Protein extraction and immunoblotting 
The protocol described by Peffley et al. [145] was used with minor changes. 
Briefly, cells were plated at 3x106 per 100 mm culture dish and allowed to attach 
for 24 hr before treating with perillyl alcohol or rapamycin as above. Cells were 
lysed in 250 pL RIPA lysis buffer containing fresh 1X Complete protease inhibitor 
cocktail (Roche Applied Science), 1 mM Na3V04 and 1 mM NaF, and protein 
concentrations were determined by a Bradford assay. Protein levels were 
assessed by western blotting according to [145] with some modifications. Fifty pg 
total protein per well were loaded on a 4-15% polyacrylamide TGX mini-gel (Bio-
Rad) and resolved by electrophoresis in 1X Tris-glycine-SDS (0.025 M Tris, 
0.192 M glycine, 0.1% SDS, pH 8.3) for 30 min at 200 volts. For western blots, 
Precision Plus protein standards (Bio-Rad) (chemiluminescence) or Odyssey® 
two-color protein molecular weight markers (infrared) were included to determine 
protein sizes. Electrophoretic transfer onto polyvinylidene fluoride (PVDF) 
membrane was performed in 1X Tris-glycine buffer. 
Membranes were stained with Ponceau red to verify protein transfer and 
loading. Membranes were blocked in protein-free blok-CH™ buffer (Millipore, 
Temecula, CA) for 1 hr at room temperature and then incubated with gentle 
rocking in one or more of the following primary antibodies: mouse monoclonal 
anti-elF4E (1:250, clone P2, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 
rabbit polyclonal elF4E (1:4,000, Cell Signaling, Danvers, MA), rabbit polyclonal 
anti-actin (1:500, clone H-300, Santa Cruz Biotechnology, Inc.), rabbit polyclonal 
anti-p70 S6 Kinase (1:1,000, Cell Signaling), rabbit monoclonal anti-phospho-p70 
S6 Kinase (Thr389) (1:1,000, clone 108D2, Cell Signaling), rabbit polyclonal anti-
Akt (1:1,000, Cell Signaling), rabbit monoclonal anti-phospho-Akt (Ser473) 
(1:1,000, clone 193H12, Cell Signaling), rabbit polyclonal anti-4E-BP1 (1:1,000, 
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Cell Signaling), rabbit polyclonal anti-phospho-4E-BP1(Thr37/46) (1:1,000, clone 
236B4, Cell Signaling) and/or rabbit monoclonal anti-hTERT (1:1000; clone 
Y182, Millipore) that also recognizes hamster TERT. All antibodies recognize the 
rodent form of their respective protein and were diluted in blok-CH™. 
Incubations were conducted overnight at 4"C and followed by extensive 
washes in 1X Tris-buffered saline (TBS)-Tween 20 (0.02M Tris, pH 7.4, 0.15 M 
NaCI, 0.05% Tween 20). Membranes were incubated with HRP-conjugated 
secondary antibodies (goat anti-rabbit or goat anti-mouse [Santa Cruz 
Biotechnology, Inc.]) were diluted 1:5000 in bl0k-CH™ buffer for 1 hr at room 
temperature along with 1 pl_ StrepTactin-HRP (Bio-Rad) per 10 mL solution to 
visualize Precision Plus protein standards (Bio-Rad). Subsequent membrane 
washes were as described [145] and then blots were incubated for 5 min in 
Immun-Star™ HRP detection system (Bio-Rad) before capturing images on a 
Kodak Image Station. Densitometric analysis of protein bands was conducted 
using Kodak Molecular Imaging Software version 4.0.4. Alternatively, 
membranes were incubated with IR-conjugated secondary antibodies (goat anti-
rabbit [IRDye 680LT] or goat anti-mouse [IRDye 800 CW] diluted 1:10000 in 
blok-CH™ buffer) and incubated for 1 hr at room temperature. Subsequent 
membrane washes were as described [145] and then blots were washed for 5 
min in PBS before capturing images on an Odyssey Infrared Imaging System 
(Licor®). Band intensities for proteins of interest were compared relative to the 
levels of actin or elF4E, which do not change in response to the above 
treatments and provide a control for loading and transfer onto PVDF membranes. 
Statistical analysis 
All experiments were conducted three to five times with sub-sampling of 
each independent quantitative experiment. Data are expressed as a mean +/-
standard deviation. Data were analyzed using Model I ANOVAs with SPSS 
version 19.0. The relationship of interest was perillyl alcohol versus control and 
rapamycin versus control; therefore, Dunnett's test was used as a follow-up to 
determine statistical significance of the results. 
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RESULTS 
Telomerase inhibition by perillyl alcohol or rapamycin is dependent on elF4E 
overexpression in immortalized CHO cells 
Telomerase expression is necessary to extend telomeres found at 
chromosome ends to compensate for the loss of telomeric DNA that would lead 
to cellular senescence. In general, somatic cells and normal cells in culture do 
not have active telomerase. In contrast, most cancer cells and cultured cells that 
survive 'crisis' and become immortalized, such as CHO, have de-repressed the 
enzyme by either transcriptional or post-transcriptional mechanisms [13, 36, 
222], We previously established that perillyl alcohol and rapamycin at 
pharmacologically relevant concentrations (400 pM perillyl alcohol for 16 hr, 10 
nM rapamycin for 4 hr), attenuated telomerase activity by over 90% in DU145 
prostate cancer cells, signifying a link between mTOR signaling and telomerase 
regulation (Chapter 2). Here we performed RTQ-TRAP on protein extracts 
obtained from rb4E and pMV7 cells first, to assess the effect of elF4E-
overexpression on telomerase activity, and secondly, to identify if elF4E-
overexpression modulates the regulation of telomerase activity in response to 
either perillyl alcohol or rapamycin under the above standard treatment 
conditions. 
Basal levels of telomerase activity based upon real time PCR CT values 
resulted in Ct values of 24.13 +/- 0.794 SD for rb4E and 24.34 +/- 1.518 SD for 
pMV7 cells. Statistical analysis demonstrated no significant differences between 
rb4E and pMV7 cells (df=2; F=0.044; p=0.845). Surprisingly however, we found 
that in the absence of elF4E overexpression, telomerase activity in pMV7 cells 
was unaffected by either perillyl alcohol or rapamycin (df=2; F=1.705; p=0.259) 
(Fig. 18). A Dunnett's test further revealed that the slight changes in telomerase 
activity in perillyl alcohol-treated (p=0.749) and rapamycin-treated samples 
(p=0.446) were insignificant as compared to the control. In contrast, in elF4E-
overexpressing rb4E cells, telomerase activity was dramatically attenuated by 
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Fig. 18. Telomerase activity is reduced in rb4E cells in response to perillyl 
alcohol or rapamycin, however pMV7 cells are unaffected. RTQ-TRAP was 
used to assess the effects of perillyl alcohol or rapamycin on telomerase 
activity in both rb4E and pMV7. Cells were treated with one of the following: 
400 pM perillyl alcohol for 16 hr, 10 nM rapamycin for 4 hr or 0.1% ethanol 
for 16 hr before lysis in CHAPS buffer. rb4E cellular extracts are 
represented by black bars; pMV7 cell lysates are represented by white 
bars. All experiments were conducted five times. Telomerase activity 
remaining was determined as described in Methods relative to ethanol 
(EtOH)-treated cells, which was set at 1 (CT value for rb4E = 24.13 +/-
0.794 SD ; Ct value for pMV7 = 24.34 +/- 1.518 SD). Error bars represent 
+/- 1 standard deviation. Asterisks depict significant differences from 
control as determined by ANOVA. 
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Fig. 19. Effects of perillyl alcohol or rapamycin on TERT mRNA levels in 
rb4E and pMV7 cell lines. Treatment conditions were as described in Figure 
18. TERT mRNA expression was determined based on CT values derived 
from quantitative RT-PCR analysis. TERT mRNA levels were normalized to 
actin expression using the delta-delta CT method and expressed as a fold-
change. Black bars represent rb4E TERT mRNA levels; white bars 
represent pMV7 TERT mRNA levels. Experiments were conducted in 
triplicate; error bars represent +/- 1 standard deviation. Asterisk depicts a 
significant difference from control as determined by ANOVA. 
respectively (df=2; F= 34.073; p=0.001) (Fig. 18). A Dunnett's test revealed 
highly significant modulation of telomerase by both perillyl alcohol (p=0.001) and 
rapamycin (p<0.0005). The observed down-regulation was similar to that 
identified previously in our studies with human prostate cancer cells (Chapter 2). 
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Neither perillyl alcohol nor rapamycin mitigates TERT mRNA levels regardless of 
elF4E overexpression 
Although perillyl alcohol and rapamycin-mediated effects on telomerase 
activity in rb4E cells were relatively rapid suggesting translational or post-
translational events, mRNA levels were assessed to verify that TERT 
transcription was not being altered. Analysis of the delta CT values of basal 
TERT mRNA levels found no significant differences between pMV7 and rb4E 
cells as assessed by quantitative RT-PCR (df=2; F=0.178; p=0.688) (not shown). 
Further, we found no inhibitory effect on TERT mRNA levels in response to 
perillyl alcohol or rapamycin treatment in either pMV7 or rb4E cell extracts (Fig. 
19). Specifically in pMV7 cells, perillyl alcohol or rapamycin had little or no effect 
on TERT mRNA levels (df=2; F=1.697; p=0.261). In rb4E cells, an ANOVA on 
treatment effects demonstrated a substantial increase in TERT mRNA (df= 2; 
F=186.48; p<0.0005); however, a Dunnett's test revealed perillyl alcohol did not 
contribute to the upregulation of TERT mRNA (p=0.782). Rapamycin, in 
contrast, significantly enhanced TERT mRNA levels 3.7-fold in rb4E cells 
(p<0.0005). However, telomerase activity was significantly down-regulated under 
these conditions as observed in Figure 18. These results clearly show that 
TERT transcription was not being hindered; therefore translational processes 
must be at play in attenuating telomerase activity in rb4E cells (Fig. 19). 
TERT protein levels are diminished by perillyl alcohol or rapamycin only in the 
presence ofelF4E overexpression 
We previously reported that in DU145 prostate cancer cells, hTERT protein 
levels decreased in response to perillyl alcohol or rapamycin treatment (Chapter 
2). Due to the apparent elF4E-dependent inhibition of telomerase activity, we 
assessed the effect of elF4E-overexpression on TERT protein modulation by 
perillyl alcohol or rapamycin treatment. Despite an ~5-fold increase in elF4E 
levels in rb4E cell extracts compared to that found in pMV7 extracts (df=2; 
F=36.941; p=0.004), the basal levels of TERT protein in both cell lines were 
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Fig. 20. TERT protein levels decrease in response to perillyl alcohol or 
rapamycin in rb4E cells but not in pMV7 cells, (a) Representative western blot 
analysis of whole cell lysates (50 yg of protein) resolved on a 4-15% 
polyacrylamide gel in presence of SDS and transferred to PVDF membrane. 
Membranes were probed with antibodies against TERT (top panel) or elF4E 
(loading control, bottom panel). Lane 1: Precision Plus Protein™ WesternC™ 
Standards. Cells were treated as described in Figure 18. (b) Densitometric 
analysis of the effects of perillyl alcohol or rapamycin on TERT protein levels 
(three independent experiments). Error bars represent +/-1 standard deviation. 
Asterisks depict significant differences from control as determined by ANOVA. 
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Fig. 21. elF4E-overexpression alters phosphorylation of S6K, Akt, and 4E-
BP1 and controls the response to perillyl alcohol or rapamycin. 
Representative examples of three independent experiments are shown. 
Rb4E or pMV7 cells were treated with biologically relevant concentrations of 
either rapamycin or perillyl alcohol as described in Fig. 18. Subsequently 
protein was extracted and 50 M9 was resolved on a 4-15% polyacrylamide 
gel in presence of SDS and transferred to PVDF membrane. Membrane 
was immunoblotted with antibodies as indicated. POH, perillyl alcohol; 
Rapa, rapamycin, EtOH, ethanol; M, protein molecular weight markers. 
virtually equivalent, therefore control bars were set to 100 (df=1; F=0.196; p= 
0.681). Upon perillyl alcohol or rapamycin treatment of rb4E cells, however, a 
34% and 51% decrease in TERT protein levels, respectively were found (df=2; 
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F=103.485; p <0.0005) (Fig. 20 (a) and (b)). A Dunnett's test further showed that 
the TERT protein responses to perillyl alcohol and rapamycin were highly 
significant in rb4E cells (p<0.0005). Rapamycin significantly decreased TERT 
protein levels despite the increase in mRNA levels. Multiple studies have shown 
mRNA levels do not often correlate to protein levels, suggesting additional 
regulatory mechanisms [223, 224]. In contrast, TERT protein levels were 
completely unaffected in pMV7 cells treated with perillyl alcohol or rapamycin 
(df=2; F=0.057; p=0.945) (Fig. 20 (a) and (b)). TERT modulation by perillyl 
alcohol or rapamycin is thus dependent on elF4E-overexpression. 
elF4E-overexpression alters phosphorylation of S6K, Akt, and 4E-BP1 and 
controls the response to perillyl alcohol or rapamycin 
elF4E-overexpression activates Akt via increased phosphorylation of 
Ser473 and likewise increases phosphorylation of S6 ribosomal protein in mouse 
fibroblasts [116]. This suggested that greater elF4E levels in rb4E may alter the 
cellular response to the mTOR pathway through a positive-feedback loop. Thus 
we examined the result of elF4E-overexpression on the levels and 
phosphorylation status of Akt (Ser473), S6K (Thr389), and 4E-BP1 (Thr37/46). 
Furthermore, we addressed the effect of perillyl alcohol or rapamycin treatment 
on the phosphorylation of these proteins. Although rb4E cells have less Akt 
protein, the protein is more highly phosphorylated than that detected in pMV7 
cells (Fig. 21). A major change in the level of Akt protein or its phosphorylation 
was not detected with either perillyl alcohol or rapamycin in rb4E or pMV7 cells. 
A comparison between pMV7 cells and rb4E cells revealed that rb4E cells had a 
more highly phosphorylated p85 isoform of S6K. S6K-phosphorylation (both 
isoforms) was almost completely abrogated by rapamycin in rb4E cells, despite 
lower levels of S6K protein compared to pMV7 cells (Fig 21). Perillyl alcohol had 
a similar, but more modest effect on S6K phosphorylation in rb4E cells. 
Strikingly, in pMV7 cells that do not overexpress elF4E, diminished S6K 







Fig. 22. A schematic representation of the positive feedback loop of elF4E 
on the mTOR pathway via NBS1. elF4E upregulation drives a positive 
feedback loop on the mTOR pathway resulting in increased phosphorylation 
of PDK1, Akt and p70 S6K. Nijmegen breakage syndrome (NBS1). 
Both rb4E and pMV7 cells had similar levels of 4E-BP1, however rb4E cells 
had a higher level of phosphorylated 4E-BP1 (center and top bands). Perillyl 
alcohol did not affect the phosphorylation of 4E-BP1 in either cell line. Likewise, 
pMV7 cells exhibited no altered 4E-BP1 phosphorylation upon rapamycin 
treatment. Conversely, reduced phosphorylation of all isoforms of 4E-BP1 was 
observed with rapamycin treatment in rb4E cells, with the 4E-BP1 isoform 
represented by the center band being the most affected. These findings support 
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the presence of a positive feedback loop where elevated elF4E in rb4E cells 
upregulates the PI3K/Akt/mTOR pathway as depicted in Figure 22 [116]. 
DISCUSSION 
Peffley et al. (2003) reported the first evidence that perillyl alcohol, limonene 
and other isoprenoids specifically affected gene expression at the translational 
level [193]. Furthermore they found that isoprenoids exerted chemopreventive 
and anti-proliferative effects, in part, by suppressing cap-dependent translation 
via mTOR/4E-BP1/elF4E cascade, specifically through decreased 4E-BP1 
phosphorylation and disruption of the elF4F cap-binding complex [145, 193], 
We recently observed that treatment of prostate cancer cells with perillyl alcohol 
and rapamycin individually was associated with a rapid and significant loss of 
telomerase activity and hTERT protein levels (Chapter 2). Of importance to this 
study was a previous finding from our laboratory that prostate tumor cells 
express levels of elF4E that are approximately five-fold greater than their normal 
epithelial cell counterpart [186], 
Although this is the first study to show perillyl alcohol or rapamycin-
mediated telomerase inhibition is dependent on elF4E, it was previously 
demonstrated that tumor cells are more responsive to perillyl alcohol-mediated 
growth inhibition than are non-cancer cells [170, 175]. Perillyl alcohol is relatively 
non-toxic and readily available through dietary sources thus making this 
compound a candidate for chemoprevention [153, 158], Although perillyl 
alcohol's mechanism of action is still not fully resolved, the current study brings 
us closer to understanding how this small molecule may be useful in cancer 
prevention. In the context of chemoprevention, elevated elF4E expression is a 
prerequisite for both perillyl alcohol-and rapamycin-dependent telomerase 
inhibition as described above (Fig. 18). elF4E is overexpressed in most cancer 
cells compared to their normal counterparts [120, 225]. Additionally, elF4E 
overexpression and telomerase re-expression both occur relatively early in the 
carcinogenesis process [35, 120], Consequently, only cells that overexpress 
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elF4E will be responsive to telomerase modulation, validating the use of perillyl 
alcohol for chemoprevention [170, 175]. 
The above results also indicate that TERT protein and telomerase activity 
are not likely regulated via enhanced elF4E-driven cap-dependent translation 
because TERT protein levels were not elevated in rb4E cells (Fig. 20). This 
finding contrasts to our previous studies that examined HMG-CoA reductase 
protein in rb4E, in which reductase expression was increased by 400 to 500 
percent compared to control cells [144, 145], This elF4E effect on reductase 
mRNA was specific and associated with only an overall 15 percent increase in 
total cellular protein synthesis. HMG-CoA reductase mRNA has extensive 
secondary structure in its 5'-UTR known to be responsive to elF4E levels. In 
contrast, the TERT 5'-UTR has minimal secondary structure (Sundin and 
Hentosh, unpublished result), suggesting that translation of this mRNA does not 
require high elF4E levels. Additionally, basal TERT mRNA levels were not 
upregulated in rb4E (Fig. 19). 
The increased TERT mRNA levels associated with rapamycin treatment of 
rb4E cells were unexpected (Fig. 19). This phenomenon may be due to 
stabilization of TERT mRNA through inhibition of protein translation by 
rapamycin. Other translation inhibitors such as cycloheximide are often 
accompanied by heightened mRNA levels attributable to mRNA stabilization and 
protection imparted by ribosomal binding, as reported for autophagy-related 
proteins and others [226-228]. Alternatively, elF4E has ancillary cellular roles 
related to protein translation including mRNA transport and turnover involving 
cytoplasmic processing-bodies (P-bodies) [219], Mammalian P-bodies are 
cellular structures enriched in 5'-3' mRNA degrading enzymes [229, 230], We 
propose that rapamycin treatment interferes with TERT mRNA association with, 
or transport to, the P-bodies, therefore enhancing TERT mRNA levels. 
Support for this conjecture is the presence of an elF4E-binding protein-4E-
transporter (4E-T) found in P-bodies that interacts with elF4E and represses 
translation [230]. elF4E itself also localizes to P-bodies [230]. The 4E-T/elF4E 
interaction serves as a prerequisite for targeting mRNAs to P-bodies. In 
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rapamycin-treated rb4E cells, 4E-BP1 was dephosphorylated (Fig. 21), which 
causes elF4E to be sequestered. Perillyl alcohol treatment did not alter the 
phosphorylation status of 4E-BP1, allowing elF4E to remain free to interact with 
4E-T. We further contend that 4E-BP1/elF4E binding supersedes the binding 
associations between 4E-T and elF4E [219]. TERT mRNA levels were not 
altered in perillyl alcohol-treated cells likely due to the integrity of the elF4E/4E-T 
complex (Fig. 19). In contrast, under rapamycin treatment, little or no TERT 
mRNA would be transported to the P-bodies; its mRNA would not be targeted for 
degradation triggering the elevated TERT mRNA levels observed in rb4E cells 
(Fig. 19). Despite high TERT mRNA levels, translation would likewise be 
negated due to elF4E binding to 4E-BP1. 
Our findings of altered TERT regulation and responses in rb4E must also be 
considered in light of recent studies that describe an elF4E feedback loop in the 
mTOR pathway [116] (Fig. 22). As depicted, elF4E-overexpression activates 
pro-survival Akt protein via increased expression of Nijmegen breakage 
syndrome 1 (NBS1) [116]. The ability of elF4E to up-regulate NBS1 is 
independent of the translation initiation functions of elF4E [116]. Once initiated 
by NBS1, the PI3K-Akt-PDK1 pathway instigates the downstream activation of 
mTOR, therefore S6K and 4E-BP1 become phosphorylated [231-233], Upon 
activation, PDK1 in turn phosphorylates S6K directly [234, 235] and PKC-
another upstream activator of S6K [236, 237]. Thus elF4E activation of PI3K 
causes three distinct phosphorylation events of S6K, thereby amplifying the 
signaling pathway. 
The redundant activation of S6K by three different proteins renders rb4E 
cells especially dependent on S6K activation rather than on 4E-BP1 activation. 
Consistent with this premise, our results show that the basal levels of S6K 
phosphorylation are greater in rb4E cells than those in pMV7 cells (Fig. 21). 
Additionally, S6K phosphorylation is dramatically curtailed by rapamycin, and 
reduced by perillyl alcohol only in the presence of elF4E-overexpression (rb4E 
cells) (Fig. 21). In contrast, minimal amplification of 4E-BP1 activation was 
observed because it is phosphorylated via direct mTOR signaling. Although 
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diminished 4E-BP1 phosphorylation was detected in response to rapamycin in 
rb4E cells, the reduction is not as great as we would expect considering the S6K 
data. The reliance of the cell on S6K activation may make rb4E cells-and by 
default TERT protein levels and telomerase activity-more sensitive to perillyl 
alcohol or rapamycin-mediated S6K inhibition. 
As cells transition from a normal condition to a cancerous state, elF4E-
overexpression may 're-wire' the mTOR pathway in such a way that a cell 
becomes more reliant on this pathway for survival and proliferation [238-241], 
Although addiction of the EGFR oncogenic signal transduction pathways 
(upstream of the PI3K-Akt-mTOR pathway) has been previously described [241], 
the elF4E-mTOR-TERT oncogenic dependence has not been demonstrated prior 
to this work. Weinstein and Joe emphasize that in cancer cells, a specific 
oncogene (i.e., elF4E) may have a more vital and altered role in a given pathway 
compared with its function in normal cells [239]. elF4E-overexpressing CHO 
cells are non-tumorigenic [242], however in our study on rb4E cells, elF4E-
overexpression mimics the behavior seen in cancerous cells and has assumed a 
role in TERT translation via S6K. If a cell such as rb4E becomes dependent on 
this pathway because of constitutive activation through elevated elF4E 
expression, mTOR inhibitors such as perillyl alcohol and rapamycin would have a 
much greater effect on these cells due to a phenomenon now known as 
oncogenic shock [238]. Our results support an oncogenic shock hypothesis in 
that perillyl alcohol and rapamycin have no effect on phosphorylation or levels of 
mTOR-associated proteins-as well as TERT-in normal pMV7 cells with low 
elF4E levels (Fig. 21). Conversely, cells over-expressing elF4E become 
sensitive to their effects. Linking elF4E-overexpression to the up-regulation of 
NBS1 may be one of the mechanisms by which elF4E causes the suppression of 
apoptosis and enhancement of survival, a phenotype associated with cancer 
cells. 
Elucidating the mechanism by which perillyl alcohol specifically manifests its 
effects against the mTOR pathway in cancer cells provides additional support for 
its efficacy as a chemopreventive agent. Similar-phytochemicals such as 
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curcumin, found in the plant Curcuma longa [218], has also been shown to have 
differential effects on protein translation in cancer cells versus normal cells [218]. 
Specifically, curcumin modulated cap-dependent translation more efficiently in 
cancer cells than in normal cells. This sensitivity may also be related to an 
activated mTOR pathway in tumor cells and account for the chemopreventive 
effects of curcumin [218]. Additional studies are necessary to further define the 
requirement of mTOR activation in prevention of cancer by natural products such 
as perillyl alcohol and related compounds. Likewise, our findings enhance the 
current understanding of perillyl alcohol's mechanism of action and highlight the 




Defining the mechanism of action of perillyl alcohol in mTOR-mediated 
regulation of telomerase activity is essential to establish the value of perillyl 
alcohol as a chemopreventive. The collective findings presented in this work are 
compelling as they provide the first evidence that perillyl alcohol modulates 
telomerase activity via the mTOR pathway in prostate cancer cells. Our 
hypothesis that perillyl alcohol modulates telomerase expression through 
translational and/or post-translational mechanisms was supported by our 
findings. We determined that telomerase activity was inhibited by perillyl alcohol 
through a reduction in hTERT protein as well as a destabilization of the hTERT-
mTOR-RAPTOR complex. Further, we revealed that perillyl alcohol or 
rapamycin-mediated inhibition of telomerase activity is dependent on elF4E-
overexpression. 
We have uncovered many novel insights into telomerase regulation. 
Surprisingly, we found that overexpression of one mTOR-regulated protein 
(elF4E) in a normal background, could in fact 're-wire' a cellular signaling 
pathway, thereby dramatically altering the way a cell responds to a drug 
(rapamycin or perillyl alcohol). Understanding these alterations in signaling 
pathways as a cell becomes cancerous will help establish new anti-cancer 
targets or improve drugs for the known targets. 
These results will also have clinical relevance for chemoprevention through 
dietary intervention. elF4E-overexpression and telomerase activation both occur 
relatively early as a cell shifts from a state of normalcy to a cancerous state, 
leaving a window of opportunity to target these cells before they multiply into a 
fully aggressive tumor mass. If the general population increases its consumption 
of fruits and vegetables, cancer rates may be decreased due to the ability of 
perillyl alcohol and other isoprenoids to dramatically curtail telomerase activity. 
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Although our study has revealed a mechanism by which perillyl alcohol 
inhibits telomerase activity, perplexing yet fascinating findings were encountered 
that present new avenues for discovery. This self-renewal pathway that we see 
repeatedly in science is our own sort of job security. The more that is discovered 
about a particular pathway/protein, the more questions arise to be answered 
about it. After this work, we are left questioning the function(s) of the hTERT-
mTOR-RAPTOR complex. We speculate that DNA repair processes may be 
controlled by the complex, although further research will be necessary to confirm 
this hypothesis. hTERT has been implicated in dsDNA repair. Furthermore, the 
mTORCI homodimer has a central cavity large enough to accommodate dsDNA. 
Additionally, mTOR is in a family of kinases (PIKKK) known for their DNA repair 
abilities. Interestingly, DU145 cells, which are radio-resistant, have very high 
levels of telomerase activity which would enable them to overcome radiation 
induced dsDNA breaks [243], Whatever the reason RAPTOR, 4E-BP1, S6K, 
Akt, Hsp90, mTOR, and TERT were linked with one another evolutionarily, we 
now know the cell has made a compromise between efficiency (i.e., pairing 
kinases with their substrates) and vulnerability to being hijacked. Both EGFR-
overexpression (upstream of the PI3K-Akt-mTOR pathway) and TERT-
overexpression can independently cause the cell to display nearly every hallmark 
of cancer (i.e., evasion of apoptosis, unchecked cell cycle progression, sustained 
cell proliferation, resistance to growth inhibition, activation of invasion and 
metastasis, and induction of angiogenesis [244]). We now know how intimate 
these two pathways are. An aspiring cancer cell need only usurp one pathway to 
then control the cancer phenotype in a multifaceted manner. 
Collectively these findings provide evidence for perillyl alcohol or rapamycin 
regulation of hTERT via the mTOR pathway in the presence of elF4E-
overexpression. Further, this work promotes the continued investigation of 
isoprenoids, such as perillyl alcohol, for use as chemopreventives. Together 
these results underscore the complexity of cellular responses that mediate anti-
tumorigenic effects. Consequently, additional studies must be directed towards 
establishing the efficacy of these agents in a clinical setting. 
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4E-BP1 4E-binding protein 1 
4E-T 4E-transporter 
m7GpppX 7-methylguanosine triphosphate 
ALT alternative lengthening of telomeres 
AMPK 5'AMP-activated protein kinase 
ATM ataxia telangiectasia mutated 
ATP adenosine triphosphate 
ATR ataxia telangiectasia and Rad3-related kinase 
BME R-mercaptoethanol 
BNIP3 BCI2/adenovirus E1B 19 kDa protein-interacting protein 3 
bp base pairs 
BSA bovine serum albumin 
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-l-propanesulfonic acid 
CHO Chinese hamster ovary 
C02 carbon dioxide 
CR4/CR5 conserved region 4 and 5 
DEPTOR DEP-domain-containing mTOR-interacting protein 
DMSO dimethyl sulfoxide 
dNTP deoxynucleoside triphosphate 
E-box Myc/Max binding site 
E6 human papillomavirus type 16 E6 oncoprotein 
EDTA ethylenediaminetetraacetic acid 
EGFR epidermal growth factor receptor 
EGTA ethylene glycol tetraacetic acid 
elF eukaryotic initiation factor 
EtOH ethanol 
FKBP12 12 kDa immunophilin FK506-binding protein 
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Abbreviations 
GAP GTPase activating protein 
GDP guanosine diphosphate 
GTP guanosine triphosphate 
H/ACA box H and ACA elements 
HCI hydrogen chloride 
HIF-1 hypoxia-inducible factor-1 
HMG-CoA Homo sapiens 3-hydroxy-3-methylglutaryl-CoA 
HRP horseradish peroxidase 
Hsp90 heat shock protein 90 
hTERC human telomerase RNA component 
hTERT human telomerase reverse transcriptase 
IRS1 insulin receptor substrate 1 
kb kilobases 
kDa kilodaltons 
KCI potassium chloride 
Map4k3 mitogen-activated protein kinase kinase kinase kinase 3 
MgCI2 magnesium chloride 
MKRN1 makorin-1 
mLST8 mammalian lethal with Sec13 protein 8; also known as G0L 
mSIN1 mammalian stress-activated protein kinase interacting protein 
mTOR mammalian target of rapamycin 
mTORCI mTOR complex 1 
mTORC2 mTOR complex 2 
Na3V04 sodium orthovanadate 
NaCI sodium chloride 
NaF sodium fluoride 
neo neomycin 
NF nuclear factor 
NK natural killer 
P-bodies processing bodies 
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Abbreviations 
PABP poly-A binding protein 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
PDCD4 programmed cell death protein 4 
PDK1 phosphoinositide-dependent protein kinase I 
PI3K phosphatidylinositide-3 kinase 
PIKK PI3K-related kinase 
PKC protein kinase C 
PML promyelocytic leukemia tumor suppressor 
POT 1 protector of the telomere 
PP2A protein phosphatase 2 A 
PRAS40 proline-rich AKT substrate 40 kDa 
PROTOR protein observed with RICTOR 
PTEN phosphatase and tensin homolog 
PVDF polyvinylidene fluoride 
Rag Ras related GTPase 
RAP1 the human ortholog of the yeast repressor/activator protein 1 
RAPTOR regulatory-associated protein of mTOR 
Ras rat sarcoma 
Rheb Ras homolog enriched in brain 
RICTOR rapamycin-insensitive companion of mTOR 
ROS reactive oxygen species 
rpm revolutions per minute 
RT reverse transcriptase 
RT-PCR reverse transcription-polymerase chain reaction 





p70 S6 kinase 
serine 
sodium dodecyl sulfate 
sarcoma 
Abbreviations 
STAT signal transducer and activator of transcription 
TBE tris-borate-EDTA 
TBS tris-buffered saline 
TIN2 TRF2- and TRF1-Interacting nuclear protein 2 
TPP1 formerly known as TINT1, PTOP, or PIP1 
TRF 1/2 telomeric repeat binding factor 1 and 2 
TSC tuberous sclerosis 
Tyr tyrosine 
ULK Unc-51-like kinase 1 
UPS ubiquitin-26 S proteasome pathway 
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